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1 Introduction 
1.1  Platelet physiology 
Platelets are highly specialized blood cells that play central roles in 
physiologic and pathologic processes of haemostasis, tumour metastasis and 
wound healing [1]. They originate from the cytoplasm of bone marrow 
megacaryocytes as anucleated subcellular fragments [2]. Platelets are the 
smallest of human blood cells (3.6 × 0.7 µM) with a life-span of 7-10 days 
[1, 2] and are present in circulation in high numbers (1.5-4.5 × 108/ml) that 
vary strongly between individuals. Since they are anucleate, platelets are 
only able to newly synthesize proteins in very confined limits as they have 
to “bring” all necessary mRNA with them from the beginning, so genomic 
effects in the classical meaning can not be observed in platelets. [3] For 
platelets all activating events culminate in aggregation, their main purpose. 
To fulfil their physiological assignments, platelets have a unique 
cytoskeleton that enables them to change their shape from discoid (non-
activated) to rounded-up with extensive formation of pseudopodia 
(activated) [1, 4] (Fig. I). 
 
non-activated activated
 
Fig. I Platelet shape change from discoid shape to formation of pseudopodia 
 
Shape change is needed for attachment of platelets to the site of injury, 
where they enact their major function. Shape change and especially all 
secretory functions of platelets are supported by the open canalicular system, 
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a dense tubular membrane system that crosses the whole cell and enlarges 
platelet membrane surface area [2, 4].  
 
The physiological role of platelets in the blood is biased. On one hand they 
are recruited to vessel wall injuries to create a physical barrier at the site of 
vessel wall damages to limit blood loss [5]. On the other hand they also 
attach to sites of ruptured atherosclerotic plaques and trigger heart attacks 
and strokes [1, 6]. The formation of a haemostatic plug requires platelet-
vessel wall (adhesion) and platelet-platelet (aggregation) interactions. The 
first step in formation of a haemostatic plug is interaction of platelets with 
van Willebrand Factor (vWF) and specific glycoproteins (GP) on the 
subendothelial surface. This interaction (adhesion) enables a firm connection 
of platelets to the injured vessel endothelium by binding to exposed collagen 
via its main platelet receptors GPIa/IIb and major collagen signalling GPVI 
receptor [7]. Initial activation and further stimulation by agents from the 
surrounding environment (i.e. thrombin and thromboxane A2 (TXA2)) lead 
to a rise in intracellular Ca2+ ([Ca2+]i) levels and subsequently to spreading 
of platelets and activation of cytosolic phospholipase A2 (cPLA2), granule 
secretion (dense and alpha granules) and activation of GPIIb/IIIa (integrin 
αIIb/βIIIa) culminating in binding of soluble fibrinogen (inside-out 
signalling) which is essential for platelet bridging and subsequent 
aggregation [1, 8, 9]. Substances secreted from dense granules include 
secondary agonists like adenosine diphosphosphate (ADP) and serotonin 
that play important roles in additional autocrine/ paracrine platelet activation 
and haemostatic plug growth [1] as they recruit more platelets to the initial 
plug. The α-granules release large adhesive proteins, mitogenic factors, 
coagulation factors as well as glycoproteins such as P-selectin (CD62) and 
CD40 ligand [1]. The latter is well recognized to induce platelet binding to 
monocytes and neutrophils. The central receptor in platelet aggregation is 
the GPIIb/IIIa (integrin αIIb/βIIIa). Cross linking of two GPIIb/IIIa 
molecules on activated platelets results in a firm connection through 
fibrinogen bridges, moreover, immobilized fibrinogen bound on stimulated 
platelets serves as an adhesive substrate for resting platelets leading to 
amplification of primary aggregation. [1]. Increase in [Ca2+]i promotes 
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efficient thrombin generation and cleavage of fibrinogen to fibrin to form a 
stable plug. All major events involved in aggregation including major 
agonists and their receptors are depicted in Fig. II. [10]. 
 
Calcium release Secretion
Kinase activation Shape change
AA-release Enzyme activation
Second messengers
 
Fig. II Intracellular events and signal transduction in platelets after initial 
activation by different platelet agonists ([10] modified) 
 
Due to activation of platelets also enzymes of the arachidonic acid (AA) 
cascade are activated. In platelets these enzymes are cytosolic phospholipase 
A2 (cPLA2), cyclooxygenase-1 (COX-1), platelet-type 12-lipoxygenase 
(p12-LO) and in a wider angle also thromboxane synthase (TX synthase). At 
least cPLA2 and COX-1 are predominately localized at the membranes of 
the dense tubular system [1]. In due course cPLA2, COX-1 and TX synthase 
are generating signalling molecules like TXA2. Also other AA metabolites as 
COX-1 metabolite 12(S)-hydroxy-5-cis-8,10-trans-heptadecatrienoic acid 
(12-HHT) or p12-LO product 12(S)-hydroxyeicosatetraenoic acid (12-
HETE) are generated after platelet activation. The role of these latter 
molecules for the events of platelet aggregation has not yet been clearly 
identified. So far, they are mostly used as markers to evaluate COX-1 and 
p12-LO activity in stimulated platelets. 
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1.2  Platelet intracellular kinase signalling cascades 
Most signalling events in platelet activation are mediated by rise of [Ca2+]i 
levels [11]. Activation of different kinase cascades and the formation of 
second messenger molecules are dependent on [Ca2+]i. As platelet 
intracellular signalling can be initiated by a wide variety of platelet agonists 
including thrombin, TXA2, ADP and epinephrine only pathways induced by 
thrombin and collagen will be discussed here in detail. Thrombin and 
collagen are considered to be strong platelet agonists as opposed to ADP and 
serotonin [12]. Soluble agonists as thrombin activate specific G-protein 
coupled receptors (GPCRs) that in turn activate their own specific signalling 
kinases in platelets. When thrombin binds to its platelet surface GPCRs, also 
known as protease activated receptors (PAR) 1/4 [13], it induces a 
conformational change of its receptors leading to activation of three major 
kinase pathways (Fig. III). 
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Fig. III Kinase signalling after thrombin stimulation of platelets 
(https://www1.qiagen.com/Geneglobe/PathwayView.aspx?pathwayID=434 modified) 
 
First (1), phospholipase C (PLC) is activated and hydrolyses 
phosphatidylinositol-(4,5)-bisphosphate liberating inositol trisphosphate 
(IP3) and diacylglyerol (DAG). IP3 binds to its receptor and induces [Ca2+]i 
mobilisation from the endoplasmatic reticulum increasing [Ca2+]i levels. 
DAG activates protein kinase C (PKC) which in turn activates its target 
enzymes or kinases by phosphorylation [13]. Increase in [Ca2+]i and 
activation of PKC [14, 15] lead to activation of cPLA2, liberation of AA and 
TXA2 formation [5, 13]. To study PKC activation, the phosphorylation 
status of its main target, myristoylated alanine-rich C kinase substrate 
(MARCKs), also can be examined [16] (not displayed in Fig. III). 
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Second (2), the phosphoinositide 3 kinase (PI3K) pathway is activated 
leading to a prolonged activation of integrin αIIb/βIIIa and stabilized platelet 
aggregates [13]. The third (3) route of signal kinases activated are mitogen-
activated protein kinase (MAPK) signalling pathways downstream of PI3K. 
p38 MAPK, which is involved in [Ca2+]i -dependent activation of cPLA2 
[14], is activated by thrombin signalling as well as the extracellular signal-
regulated protein kinases (ERK1/2). However, the functional outcome of 
ERK1/2 activation in platelets is so far not fully understood [13]. But since 
maximum phosphorylation of ERK1/2 occurs approximately 2 to 3 minutes 
after cell stimulation those kinases have probably only a secondary 
involvement late in aggregation events [13]. Protein kinase B (PKB), also 
known as Akt, is also activated in platelets by thrombin stimulation and 
plays an important role in platelet thrombus formation and stabilisation [17, 
18]. All these events lead to prominent platelet aggregation [5]. 
Collagen also activates PKC and PI3K and these, as in thrombin signalling, 
generate second messengers IP3, DAG and PIP3 [5]. Not all signalling 
proteins and interaction partners are displayed in this simple overview (Fig. 
IV).  
Collagen
?
PLCγ2 DAGIP3PIP3
PI 3-kinase
GPVI receptor
outside
inside
 
Fig. IV Collagen-induced kinase signalling ([5] modified) 
 
How other kinases such as p38 MAPK and ERKs are activated is not quite 
clear as collagen signalling in platelets seems to be very diverse and not all 
pathways have been elucidated completely. Nevertheless, collagen-induced 
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activation of kinases takes different pathways than kinase activation by 
thrombin as could be proved for PKC activation where two different 
regulatory mechanisms could be identified [19] and also different isoforms 
of PKC are activated (Fig. III, Fig. IV). All of the kinases that are activated 
when platelets are stimulated with thrombin or collagen promote platelet 
activation. Platelet activation always implicates activation of residing 
enzymes like cPLA2, COX-1 and p12-LO. 
 
As platelets are involved in the genesis of many cardiovascular disorders 
platelet inhibition bears a tremendous significance for treatment of these 
diseases. Negative regulation or platelet inhibition is essential to prevent 
uncontrolled thrombosis. In this regard the role of nitric oxide and 
prostacyclin (prostaglandin I2, PGI2) are well established. These mediators 
regulate platelet function by increasing intracellular concentrations of cyclic 
nucleotides cGMP/cAMP via guanyl and adenyl cyclase activation and 
thereby decrease platelet activity [20]. Antiplatelet agents such as aspirin 
suppressing TXA2 formation and abciximab blocking GPIIb/IIIa receptor 
signalling are used to impair platelet activation in cardiovascular disease 
[21]. One prominent pathway down regulating platelet activity and thereby 
activity of platelet enzymes involves increase of intracellular cAMP and 
activation of cAMP dependent protein kinase A (PKA). Phosphorylation of 
PKA target proteins occurs at serine and threonine residues [22] and leads to 
their inhibition in most cases. PKA involvement in inhibition of platelet 
adhesion and shape change could already be established [23, 24]. PKA also 
seems to be involved in regulation of [Ca2+]i mobilisation [25]. A negative 
regulation of platelet intracellular enzymes as p12-LO via PKA pathways 
seems likely as PKA is strongly expressed in platelets [25] and has mostly 
inhibitory functions. To activate PKA by increasing cAMP levels 
prostaglandin E2 (PGE2) can be used although no specific PGE2 receptor has 
been identified on platelets and PGE2 also seems to induce different 
reactions depending on the applied concentration [26]. However, a rise in 
cAMP levels could be induced by 5 µM PGE2 addition to rat and pig 
platelets [27] and proved to be an efficient tool to elucidate PKA functions 
and cAMP properties in platelet regulation.  
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A second route leading to platelet inhibition seems to be provided by protein 
tyrosine phosphatase (PTP) activity that are apparently essential for platelets 
to avoid activation [28]. Inhibition of PTP caused platelet aggregation, 
secretion and TXA2 formation [13], yet a precise role for PTP in platelets 
has to be established. 
1.3  Cytosolic phospholipase A2 (cPLA2) 
Most platelet functions including aggregatory events depend on AA 
metabolism as some important signalling molecules as TXA2 are derived 
from AA. To start the synthesis of prostaglandins and thromboxanes, the 
most important AA metabolites synthesised in platelets, AA has to be 
released from the cell membrane phospholipids as starting point of the AA 
cascade (Fig. V).  
 
Arachidonic acid
12-HETE
Prostanoids, 12-HHT
p12-LO COX-1
cPLA2
PGH2
Isomerases
 
Fig. V Arachidonic acid pathways: main metabolic activities in platelets 
 
To release AA, human platelets contain significant amounts of cytosolic 
cPLA2 [29] that is thought to be the main phospholipase providing AA for 
aggregatory events [30]. The enzyme has a molecular weight of 95 kDa and 
is found in the cytosolic fraction of platelets. To access its substrate, 
preferentially arachidonate containing phospholipids, at the plasma 
membrane cPLA2 has to bind Ca2+ to be able to access the plasma 
membrane [30-32]. cPLA2 activity is strongly [Ca2+]i -dependent and rises 
approximately 10-fold as [Ca2+]i increases from levels in resting cells (< 100 
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nM) to levels measured in activated cells (300 nM). If only little [Ca2+]i is 
present, only a very low cPLA2 activity can be observed [33]. Inhibition of 
cPLA2 is followed by inhibition of major platelet functions accompanied 
and in part caused by reduction of activity of down stream enzymes 
dependent on AA release as COX-1 or p12-LO [34]. 
1.4  Cyclooxygenase-1 (COX-1) 
After liberation of AA from the membrane, AA is metabolised via different 
pathways. One pathway runs via p12-LO metabolism and will be discussed 
in detail (1.5.2). The other pathway in platelets involves COX-1. 
Metabolites from the COX-derived precursor PGH2 such as TXA2 and 
prostacyclin (PGI2) exert important functions in platelet aggregation and 
regulation of vessel wall tone [26]. COX-1-derived arachidonate metabolites 
are outlined in Fig. VI, platelet specific products are indicated (red squares). 
 
Fig. VI Formation of prostanoids derived from cyclooxygenase pathways  
 
COX-1 is constitutively expressed in many tissues such as blood vessel wall, 
platelets and renal tubulus cells [35] and performs mostly house-keeping 
functions for vascular haemostasis, gastric mucosal integrity and renal blood 
flow. It exists as homodimer with a molecular weight of approximately 70 
kDa [36, 37]. COX-1 is a bifunctional enzyme with both cyclooxygenase 
and peroxidase functions as displayed in Fig. VI. COX-1 metabolizing 
activity ceases after a couple of minutes in a suicide inactivation mechanism 
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[38, 39]. Only unbound fatty acids such as free AA can be used as a 
substrate by COX-1 [40].  
 
Besides substrate supply also the intracellular redox state of the cell is 
important for COX activity and therefore platelet functions. The intracellular 
redox state of platelets is controlled by endogenous generation of reactive 
oxygen species (ROS) after platelet activation by thrombin or collagen [41]. 
ROS generation after platelet activation was first observed in 1977 by 
Marcus et al [42] and platelet-derived ROS seem to play an important role in 
aggregation and recruitment of platelets to an already existing haemostatic 
plug as well as in overall modification of platelet functions [41, 43]. Any 
inhibitory substance that is able to lower intracellular hydroperoxide 
concentrations beneath 10 nM by inhibiting ROS generation potently 
inhibits COX-1 activity [38]. The oldest route commonly known to inhibit 
COX-1 activity and therefore TXA2 synthesis and platelet activation uses 
irreversible acetylation of COX-1 in platelets by low dose acetylsalicylic 
acid (ASS). As platelets are anucelate cells with only a small capability for 
de novo protein synthesis [3], the COX-1 inhibition persists for the life-span 
of the platelets as COX-1 protein cannot be renewed [36]. This acetylation 
effect is used in long-time preventive therapy of cardiovascular disease.  
 
For studies not directly investigating COX-1 its products can be used as a 
convenient control activity of other platelet enzymes as p12-LO to check, 
for instance, selectivity of investigated effects on these enzymes. In this 
context the stable metabolites TXB2 and 12-HHT are often measured as 
parameters for COX-1 activities as they can easily be analyzed by ELISA 
(enzyme linked immunosorbent assay) and HPLC (high performance liquid 
chromatography), respectively. 
 
In conclusion, platelets would not be able to fulfil their important functions 
in haemostatic events without the endowment with cPLA2 and COX-1. 
However, these two enzymes are also important players in platelet 
dysfunctional properties as cardiovascular disease and as such in the focus 
of antiplatelet therapy. 
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1.5  Platelet-type 12-lipoxygenase: Occurrence and 
(patho-) physiology 
1.5.1  Human 12-lipoxygenases 
In 1974 a new enzyme in human platelets metabolizing arachidonic acid was 
identified by M. Hamberg and B. Samuelson [44]. This enzyme was 
characterized as a 12-lipoxygenase (LO) and was the first LO to be 
identified in mammalian tissues. So far, only plant LOs were known [45] 
and it was believed that “there was no lipoxygenase in animal tissues” [46]. 
Later on, other 12-LOs were found to be expressed and catalytically active 
in many different mammalian tissues, i.e. in porcine leukocytes [47], bovine 
platelets [48] and mouse epidermis cells [49]. Until today, functions and 
catalytic properties of the different LOs that were identified until now are 
studied intensely. Lipoxygenases (E.C.1.13.11.) are a family of non-heme 
iron containing dioxygenase enzymes that introduce molecular oxygen into 
unsaturated fatty acids such as AA or linoleic acid [46, 50]. The individual 
LOs are named after the oxygenation position at which they introduce 
oxygen into their respective substrate. So far, 5-, 8-, 12- and 15-LOs have 
been identified in mammals [45, 51-53]. In human, 5 different LOs have 
been identified [54], namely 5(S)-, 12(S)- and 12(R)- and two distinct 15(S)-
LOs (Fig. VII). 
 
Fig. VII Human LOs and their metabolic products 
 
3D X-ray structures are so far only available for soybean 1-LO and rabbit 
reticulocyte 15-LO [55, 56]. Molecular modelling comparisons of proposed 
amino acid sequences of the different non-crystallized LOs showed that the 
catalytical domain is very well conserved in all animal and plant LOs [55, 
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56]. Together, plant and animal LOs show a huge diversity of proteins (Fig. 
VIII [57]). 
 
Fig. VIII Phylogenetic tree of LOs [57] 
 
The main oxygenation site for 12-LOs is the C12 of AA or other fatty acids 
that can be used as substrate. However, as 12-LOs differ strongly with 
respect to homology in amino acid sequence, substrate preferences, 
dependence on cofactors and inactivation mechanisms [50] a more detailed 
characterization of the individual 12-LOs is necessary. The group of 12-LOs 
contains three isoforms, p12-LO and its isoforms leukocyte- and epidermis-
type12-LO [50, 57, 58]. As the leukocyte 12-LO show more homologies in 
amino acid sequence to the human and rabbit 15-LOs and also create 
considerable amounts of a 15-oxydized product [50], they have been more 
correctly classified as 12/15-LOs. The platelet- and leukocyte isoforms share 
57-66% amino acid homology [46] deduced from their cDNA composition. 
The epidermis-type 12-LO stands a little outside the group as it is the only 
12-LO that produces 12(R)-HETE instead of the (S)-isomer. In this context 
it fits that murine epidermis-type 12-LO that also turns out 12(R)-HETE as 
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metabolite shows a 54% homology in amino acid structure to this recently 
identified 12(R)-LO in humans [59], although other studies propose a 84% 
homology [60]. Antibodies raised against the different isoforms show no 
cross reactivity [61] which further strengthens the differences between 12-
LO isoforms. 12-LOs are very widely distributed in many cell types and 
tissues [46, 50, 62]. To name a few, p12-LO is expressed in human, ovine, 
rat and murine platelets [62, 63], human and murine epidermis cells [62, 64] 
and prostate [65] and skin cancer cells [66]. Leukocyte 12-LOs can be found 
in mouse macrophages, rat and rabbit leukocytes [50], whereas the 
epidermis type 12-LO so far could only be identified in mouse tissues [50]. 
Human 12(R)-LO was found to be expressed in human skin [67] aggravating 
its affiliation with murine epidermis-12-LO and making it the “human 
epidermis 12-LO”. Simply considering such a variety of enzymes it is not 
surprising that substrate specificities and formed products also vary between 
the different isoenzymes [46, 50].  
 
Leukocyte 12-LOs are able to metabolise AA as well as C18 and C22 fatty 
acids, and even phospholipids and esterified fatty acids can serve as a 
substrate [46, 68, 69]. In contrast, p12-LO are only able to metabolise C20-
fatty acids [48, 69], in humans only arachidonic acid is metabolised. The 
epidermis isoforms preferably use esters of the respective fatty acids as 
substrate rather than the free non-esterified acids [50, 58]. The main 
metabolite of all 12-LOs consists of 12(S)-hydroxy-5,8,10,14-
eicosatetraenoic acid (12(S)-HETE) [50] except for the epidermis 12(R)-LO 
and was first found in human and bovine platelets [44, 70]. Leukocyte 
isoforms also produce the equivalent 15(S)-HETE in a fixed ratio to 12(S)-
HETE which was established in porcine leukocytes at 9:1 (12-:15-HETE) 
[68]. The exact numbers of the ratio between the two metabolites depends 
on the enzyme. This double outturn of metabolites is specific for leukocyte 
12-LO, hence as mentioned the naming of the enzyme group as 12/15-LO. 
1.5.2  Platelet-type 12-lipoxygenase (p12-LO) 
p12-LO is only able to produce one metabolite, 12(S)-HETE, from its - in 
human - only substrate, arachidonic acid. Only this metabolite could be 
identified during own studies, although a 15-LO activity was proposed for 
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platelets as well [71]. Structures of the main 12/15-LO metabolites and a 
short overview of the possible metabolism pathways are given in Fig. IX 
[46]. 
 
Fig. IX Metabolism of arachidonic acid by different LOs 
(www.benbest.com/health/Lipoxygenase.jpg)  
 
The peroxidized products (HPETEs) are metabolised to their stable products 
by peroxidase activity. Metabolites used as parameters for activity 
determination are the “HETEs”. Also duration of metabolic activity varies 
between the isoforms. In fact, catalytical activity of leukocyte 12-LOs 
ceases after a few minutes due to suicide inactivation of the enzyme [46, 58, 
62, 72] in contrast to the p12-LO isoform which is active over long time 
periods [73]. The enzyme reaction catalyzed by p12-LO proceeds almost 
linearly over 30 minutes [48, 74] and p12-LO keeps producing 12-HETE 
over even longer periods up to 115 minutes [73]. Even without stimulation a 
basal spontaneous p12-LO activity in intact cells can be measured [75, 76]. 
12-LOs have been studied extensively in pathophysiological contexts. 
Leukocyte 12/15-LO activity has been connected to many different disorders 
including genesis of atherosclerotic events in connection to their ability to 
oxidize LDL [77, 78] and diabetic disorders [79]. Epidermis-type 12-LO 
involvement in development of psoriasis in human has been established as 
its metabolite was found to be enriched in psoriatic skin [67]. p12-LO was 
the first mammalian LO to be identified [44] and has been extensively 
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studied. Still, only little is known about p12-LO activation, regulation of its 
activity and its physiological relevance. Its genetic locus has been precisely 
mapped to chromosome 17p13 [80] with a size of 13-17 kb, about twice as 
large as the genes for its leukocyte and epidermis isoforms. p12-LO is 
recognized as protein in platelet homogenates by specific antibodies as a 
protein of approx. 72 kDa. Its exact secondary structure can only be 
proposed along the crystallized structure of soybean 1-LO and rabbit 
reticulocyte 15-LOs [55, 56, 81], as no X-ray crystallized structure has yet 
been analyzed for p12-LO. A calculated structure was proposed by Aleem et 
al [82] and is depicted in Fig. X. 
Non-heme iron
 
Fig. X Proposed 3D-structure of (a) p12-LO based on (b) soybean 1-LO structure 
([82] modified) 
 
How protein expression of p12-LO is regulated has scarcely been 
investigated. Nevertheless, regulation of expression by cytokines, 
interleukin 1 beta (IL-1β) and epidermal growth factor (EGF) has been 
proposed [83-85]. To keep in mind, different mechanisms of protein 
expression have to be assumed for p12-LO as platelets are anucleate and 
only able to perform limited protein biosynthesis. All p12-LO protein or the 
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respective mRNA must be generated before platelets are released into the 
blood stream.  
p12-LO’s main substrate arachidonic acid is metabolised to 12(S)-H(P)ETE 
and subsequently to 12(S)-HETE by a peroxidase activity [86]. p12-LO 
activity can also be induced by platelet stimulation with collagen or 
thrombin [87], although for collagen far higher concentrations are needed to 
induce p12-LO activity than for platelet activation during aggregation [69]. 
Thrombin concentrations used for aggregation studies are also effective to 
activate p12-LO [88, 89]. As collagen and thrombin are the main signalling 
agonists for platelets in physiological contexts [1], a connection of collagen 
and thrombin signalling pathways and p12-LO activating pathways can be 
assumed. There is evidence indicating a signalling cascade which originates 
at the Glycoprotein VI cluster receptor (GPVI) for collagen at the platelet 
membrane to activate p12-LO via PI3 kinase and [Ca2+]i mobilisation [87, 
90]. The proposed signalling cascade is more closely portrayed in Fig. XI 
[87, 90].  
On the other hand, p12-LO is far more independent from [Ca2+]i levels for 
activation as for example 5-LO in polymorphonuclear leukocytes (PMNL) 
[91]. In contrast, p12-LO can function without [Ca2+]i if enough substrate is 
present [92]. A role for [Ca2+]i elevation in activation of p12-LO is unclear, 
in particular as p12-LO displays a basal, constitutive activity. However it 
must be noted that most studies addressing p12-LO activation, measured as 
12-H(P)ETE formation did not consider cPLA2 as a critical component 
which releases AA as substrate for p12-LO. So to stimulate p12-LO activity 
also A23187 (Ca2+-ionophore) and p12-LO substrate AA can be used [93]. 
p12-LO shows a very high throughput for its substrate arachidonic acid. 
Dkcat/Km was found to increase temperature dependently to very large values 
showing a Km of 8 µM for AA [74, 92, 94].  
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Fig. XI Activation of p12-LO by collagen signalling ([87]) 
 
The subcellular localisation of p12-LO in human platelets is a matter of 
debate. Subcellular localisation is proposed to be predominantly cytosolic by 
some authors [70, 74, 95, 96] or thought to be only at the platelet 
membranes by others [97]. In some studies p12-LO was found to be located 
mostly (65%) in the membrane or microsomal fractions of platelets [92]. 
The subcellular localisation might be connected to p12-LO activity 
demonstrated by translocation and activity studies of the enzyme [95, 98]. 
The enzyme liberating AA, cPLA2, translocates to the plasma membrane 
[15], so an accompanying translocation of p12-LO seems likely as p12-LO 
needs to access its substrate at the plasma membrane.  
Neither regulation of p12-LO activation nor inhibition was so far correlated 
to a certain signalling pathway. p12-LO seems to be an enzyme that is 
permanently active, as a basal 12-HETE formation can be measured in non-
stimulated platelets [75, 76]. Considering this circumstance an inhibitory 
regulation of p12-LO seems more likely than an activating regulation. PKA 
is a inhibitory kinase of many platelet functions and inhibitory regulation of 
p12-LO might be achieved via PKA signalling, even more probable since 
p12-LO actually contains a phosphorylation motif for PKA (Fig. XII) [99]. 
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Fig. XII Phosphorylation sites for PKA ([99] modified) 
 
To assign a pathophysiological role to p12-LO and its metabolite 12-HETE 
one has to discriminate between platelet and leukocyte 12-LO. Most (patho-) 
physiological roles of p12-LO and its metabolite 12(S)-HETE that have been 
identified so far could be attributed to both enzymes as both have the same 
main product and physiological functions of both enzymes may overlap. 
One has to take into account that some diseases like diabetes or 
atherosclerosis attributed to leukocyte 12-LO could well be purveyed also 
by p12-LO as the effective metabolite 12-HETE is produced by both 
enzymes. p12-LO was specifically identified to be involved in the 
mechanisms regulating platelet aggregation. Sekiya et al [100] were able to 
trace back regulation of platelet aggregation to 12-HETE, identifying a 
negative feedback mechanism that prevents excessive aggregation. When 
p12-LO was knocked out in mice using targeted gene disruption, an 
increased platelet sensitivity to ADP as agonist for platelet aggregation was 
observed [101]. In 2000, Akiba et al. found p12-LO product formation to be 
important for inhibition of platelet aggregation [102]. Together, p12-LO and 
its product 12(S)-HETE seem to be closely related to functioning platelet 
aggregation and its regulation. Also the timely progression of aggregation 
seems to depend on p12-LO activity and its product 12(S)-HETE as 12(S)-
HETE supports the switch from primary agonist collagen to secondary 
agonist thrombin [103]. The most prominent connection of p12-LO product 
12(S)-HETE to any pathophysiological events that has been observed so far 
is its role in cancer metastasis, invasiveness and motility of tumours as well 
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as angiogenesis connected to tumour growth [104-106]. p12-LO has been 
identified in human melanoma cell lines [107] and skin cancer cells [66] on 
mRNA and protein levels. Inhibition of 12-LO led to apoptosis of cancer 
cells in a gastric cancer cell model [108] although it was not clearly 
identified whether leukocyte or platelet 12-LO was investigated in this 
study. Nevertheless, apoptosis and cell survival of cancer cells seems to be 
regulated by 12-LO or its metabolite 12(S)-HETE [109]. Besides its 
involvement in skin carcinogenesis, p12-LO is closely connected to prostate 
cancer [110-113]. There is also evidence for a role of p12-LO in 
angiogenesis and tumour growth in these studies. Angiogenesis in particular 
seems to depend on p12-LO expression and activity [109, 113]. Also 
propulsion of endothelial sprout formation and modulation of angiogenesis 
has been proposed [114]. Invasive potential of different cancers was brought 
into connection with p12-LO activity as well [115]. Besides its apparently 
strong involvement in the different stages of cancer p12-LO is also involved 
in the genesis of psoriasis. 12(S)-HETE is a strong chemotactic stimulus for 
leukocytes and other epidermal cells [116] and p12-LO is expressed in 
epidermal cells in psoriasis [117] as is the human epidermis-type 
isoform12(R)-LO [67]. On the other hand, if one keeps in mind that p12-LO 
is producing its metabolite without stimulation over time periods of hours, 
one could possibly attribute p12-LO to “house-keeping” functions of a 
constitutively expressed protein with a basal continuously sustained activity. 
 
Concerning p12-LO metabolites, not only 12-HETE should be mentioned 
but also lipoxins, the generation of which has been attributed to p12-LO 
metabolic functions. Lipoxins are tetraene containing eicosanoids with 
selective biological functions that are generated by single cell types or cell-
cell interactions [118, 119]. In human tissues two major biosynthetic 
pathways for lipoxins are found, one metabolizing 15-H(P)ETE, the other 
being a transcellular route involving cell-cell interactions between platelets 
and PMNL in the conversion of leukocyte-derived LTB4 [118, 120]. 
Lipoxins are involved in multifactorial events such as thrombosis and 
atherosclerosis whenever a cell-cell interaction of platelets and leukocytes is 
likely to occur in vivo [121].  
  20 
Although p12-LO and its metabolites have been studied in many of their 
functions in vivo, still a lot of questions remain unanswered. However, a 
connection seems to exist between p12-LO activity and platelet functions. 
Moreover, as platelets are also involved in many central processes in cancer, 
inflammation and cardiovascular disease [4, 122, 123], a role for p12-LO 
and its metabolite 12-HETE seems likely. 
1.6  Gender bias in inflammatory and cardiovascular 
disease 
Modern medicine has increasingly focused on gender medicine in the last 
years. Sex hormones (progesterone, testosterone, estradiol) do not only 
affect sexual maturation and reproduction but also influence the immune 
system [124]. In the field of inflammatory diseases, a clear gender bias 
could be identified and the susceptibility for certain inflammatory diseases is 
far more prominent in the female sex. More women than men are affected 
by autoimmune disorders as rheumatoid arthritis and systemic lupus 
erythematosus. This observation has been connected to sex hormone levels 
and different production of cytokines [124, 125]. Other inflammatory 
diseases as asthma have been found to shift to a higher incidence in females 
after sexual maturity, an outcome related to a change in hormonal status 
after puberty [126]. In 2008, Pergola et al. proposed a pharmacological 
mechanism underlying gender disparities in inflammatory diseases linked to 
5-LO activity and leukotriene formation [127]. Inhibitory modulation of 5-
LO by sex hormones, in particular androgens, was uncovered explaining a 
lower leukotriene formation and therefore lower incidence for inflammatory 
diseases in the male sex.  
But not only in inflammation is a gender bias a well known fact. Thus, an 
excess of cardiovascular complications in the male sex in comparison to the 
female sex has been observed [128]. As risks for cardiovascular disease rise 
after menopause, a regulation of platelet aggregation and thrombosis by 
female sex hormones, especially by progesterone, seems likely as 
progesterone production in the female ceases after menopause [129]. A high 
risk of cardiovascular events also accompanies the use of oral contraceptives 
that change the hormonal status in females. Oral hormone replacement 
therapy after menopause reduces cardiovascular risks [130]. Some studies 
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performed in vivo or in vitro established a differential regulation of platelet 
aggregation between male and female species. Platelet aggregation and 
secretion diminished in platelets of female pigs after sexual maturity in 
comparison to platelets isolated from male pigs [131], platelets isolated from 
male rats showed a greater aggregation than female platelets [132], and 
platelets from male and female human donors reacted differently to low-
dose aspirin therapy [133]. However, the results are not as clear as for 
inflammatory disease and some groups found female platelets from different 
species to be more reactive than male, at least in untreated conditions [133, 
134]. Nevertheless, a prominent role for sex hormones in regulation of 
different disorders seems obvious. 
1.7 Progesterone and progesterone receptors 
Progesterone is mainly involved in the regulation of normal female 
reproductive function controlling release of mature oocytes, facilitation of 
implantation and maintenance of early pregnancy, promoting uterine growth 
and suppressing myometrial contractility in uterus and ovaries, preparing 
breast tissue for milk secretion and milk protein production in the mammary 
gland, and mediating signals required for sexually responsive behaviour in 
the brain [135]. Progesterone (Fig. XIII) is synthesised mainly in the ovaries 
[135].  
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Fig. XIII Chemical structure of progesterone and progesterone plasma levels 
 
Its secretion changes strongly during the menstrual cycle which can roughly 
be divided into two main phases, the follicular phase where progesterone 
plasma levels are low and the luteal phase with a high plasma level of 
progesterone (Fig. XIV). Before ovulation granulosa cells in the follicle are 
responsible for biosynthesis and secretion of estradiol (follicular phase). 
After follicle rupture (ovulation) the same granulosa cells form the corpus 
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luteum and as such start secreting progesterone (luteal phase). If no 
fertilisation occurs, the corpus luteum will degrade and menstruation 
proceeds. If fertilisation occurs, the corpus luteum continues to secrete 
progesterone during the first two to three months of early pregnancy until 
the placenta commences progesterone biosynthesis for pregnancy 
maintenance [135]. Progesterone plasma levels rise to very high 
concentrations of approximately 1000 nmol/l or even higher during  
pregnancy, the highest levels are reached at the end of the third trimester. 
Fig. XIV Progesterone plasma levels (http://www.biorama.ch/biblio/b90laka/lakap/pro010.htm) 
 
Once released from the ovaries, progesterone is transported in the blood by a 
progesterone carrying protein, transcortin, as opposed to binding of estradiol 
and testosterone to sex hormone binding globulin (SHBG) [136]. Finally in 
menopause, progesterone synthesis and secretion are reduced [129] as 
natural female fertility comes to an end. A short overview about the most 
important functions of progesterone in its target tissues during the normal 
reproductive phase of females is also given in Fig. XV.  
 
Fig. XV progesterone functions in target tissues ([135]) 
 
Effects of progesterone have classically been attributed to primarily genomic 
influences affecting protein expression and activation of nuclear receptors. 
Those “classical” modes of action of progesterone include regulation of 
gene expression in reproductional tissues as uterus and ovaries. Progesterone 
effects are mediated by its classical nuclear receptors that have initially been 
characterized in mammalian uterus in the early 70’s [137] and have been 
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found since then in many other human tissues. Two receptor subtypes have 
been identified and were characterized as progesterone receptors (PR) A and 
B, with the molecular masses of 81 and 115 kDa, respectively. The classical 
PRs fit into a large family of ligand-activated nuclear transcription 
regulators including receptors for other steroids as androgens or estradiol, 
retinoids, vitamin D and thyroid hormones [135]. In the absence of their 
ligand (i.e., progesterone) steroid receptors as PR exist in the cells as 
inactive complexes in the cytoplasm. Upon ligand binding they translocate 
to the nucleus and activate transcription of target genes [138], promoting 
protein biosynthesis and cell growth. Detailed molecular mechanisms of 
these regulatory functions are not known [135].  
A second mode of action for steroid receptors besides the one described 
above mediates its actions via direct protein-protein interaction with 
transcriptional factors, repressing the activity of these factors. Those two 
modes of action both require translocation of the receptor-ligand complex to 
the nucleus and take at least 30 to 60 min [138].  
 
In the last few years, other regulatory pathways of steroid hormones as 
progesterone have been proposed, mediating steroid effects in a fast, non-
genomic way by activation of kinase signalling pathways or by direct 
influence on cellular structures [139]. So far, direct activation of MAP 
kinases, adenylylcyclase, PKC and GPCR has been described [138, 140]. 
Some of these actions are conveyed by the classical receptors but also new 
membrane-bound receptor subtypes have been identified proposing a 
completely new concept for sex hormone actions. A detailed classification 
of possible modes of non-genomic actions is given after the so-called 
Mannheim Classification in Fig. XVI. 
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Fig. XVI Mannheim classification of non-genomic steroid actions [141] 
 
Note that genomic actions are always connected to the existence of a 
nucleus in the cell and the possibility of de novo protein and mRNA 
synthesis. Genomic actions of progesterone depend on binding of 
progesterone plus its receptor to nuclear DNA and always affect their target 
tissue via regulation of DNA transcription and protein translation. This 
difference between genomic and non-genomic effects cannot be stressed 
enough (Fig. XVII). 
 
 
Fig. XVII Differentiation between genomic and non-genomic actions ([139]) 
 
Genomic regulatory effects in this definition cannot be observed in 
anucleate cells as platelets. Recently, also membrane-bound receptors unlike 
the classical steroid receptors could be identified by the use of BSA-coupled 
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and fluorescence marked steroids. Steroids could not enter the cells but still 
conveyed their actions although localised extracellularly at the cell 
membranes [141] where binding to non-nuclear receptors would occur. A 
good example for rapid actions of progesterone is the acrosome reaction 
observed in sperm cell maturation. Thus, progesterone induces sperm cell 
maturation in human sperm by stimulating a rapid [Ca2+]i elevation and 
induction of acrosome reaction. In this process, a [Ca2+]i dependent rise in 
intracellular cAMP leads to activation of PKA. Involvement of PKC has 
also been discussed [142, 143]. As classical progesterone receptor 
antagonist, RU 486 (mifepristone) that has a very high affinity to the 
progesterone receptor, may be even higher than progesterone itself [144] is 
only a weak antagonist of the progesterone induced acrosome reaction. 
Synthetic progestins normally potent activators of transcription via 
progesterone receptors are also only weak inducers of the acrosome reaction, 
the participation of a different kind of progesterone receptor was implied 
[141]. The presence of N-terminally truncated forms of the classical PR of 
approximately 50 kDa that could be detected by an antibody against the c-
terminus of PR were reported and characterized by one group [145, 146]. 
This truncated form predominantly localizes to the plasma membrane and 
could be the mediator of progesterone effects on acrosome reaction via PKA 
and PKC. Non-genomic actions of steroid receptors that might be mediated 
by novel membrane receptors propose a new opportunity to explain rapid 
actions of the respective ligands that so far have only been connected to 
genomic regulation of protein expression and long-term effects. 
Progesterone aptitudes in induction of various reactions and activation of 
different signalling pathways are far more diverse than has been suggested 
to this point. Progesterone might be involved in rapid regulation of enzyme 
properties in nucleated as well as in non-nucleated cells. 
1.8  Cinnamyl-3,4-hydroxy-α-cyanocinnamate (CDC) 
In 1991, a series of new caffeic acid derivatives was synthesised that were 
identified to have a high potency to inhibit p12-LO [147].  
One of these derivatives is now known as cinnamyl-3,4 hydroxy-α-
cyanocinnamate or CDC. Its chemical structure is displayed in Fig. XVIII.  
  26 
O
O
OH
OH
CN
CDC
 
Fig. XVIII Chemical structure of CDC 
 
The substance is coloured in an intensive yellow which can be explained by 
its extensive system of electron delocalisation. In standard HPLC analysis 
also a strong UV absorption of CDC at 280 nm can be observed at 
concentrations above 3 µM. Caffeic acid itself was known as a LO inhibitor 
with a high potency although a low selectivity for LO that blocks 5- as well 
as 15-LO activities [148, 149]. Introduced modifications were found to 
increase selectivity towards 12-LO. Inhibitor screening tests revealed an 
IC50 of 0.063 µM for isolated enzyme preparations of p12-LO [147]. The 
IC50 determined for 5- and 15-LO were much higher, 1.89 µM and 3.33 µM, 
respectively. Hence, CDC was designated a selective p12-LO inhibitor. 
However, CDC was only defined in cell-free enzyme preparations whereas 
cellular conditions have been neglected. Neither was defined which class of 
LO inhibitor it belonged to as there are many different possible mechanisms 
for LO inhibition such as iron ligand, redox active or non-redox 
competivitve inhibitors [91]. Still, CDC is often used to inhibit p12-LO or 
leukocyte 12-LO in cellular assays to determine the pathophysiological role 
of 12-LOs and their metabolites in cancer metastasis [113], monocyte 
adhesion [150], diabetic nephropathy [151], hypertension [152], 
vasodilatation [153], platelet activation [154] and many other research 
projects investigating disorders possibly connected to 12-LOs. In regard of 
the chemical structure of CDC, some other properties are brought to mind as 
CDC exhibits a potent redox system at its hydroxylated phenyl moiety and 
also possible iron- or Ca2+ -chelating properties could be proposed. In case 
CDC would change intracellular redox state of investigated cells or block 
[Ca2+]i signalling by chelation, the use of CDC as “12-LO inhibitor” might 
lead to fatal misinterpretations of obtained results for involvement of 
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investigated cell functions in certain disorders. Many possibilities and 
molecular targets yet undiscovered necessitate a more thorough 
investigation of CDC functions in cellular systems. 
1.9  MK-886 
The indole derivative 1-[(4-chlorophenyl)methyl]-3-[(1,1-
dimethylethyl)thio]-α,α-dimethyl-5-(1-methylethyl)-1H-indole-2-propanoic 
acid (sodium salt) (Fig. XIX), also known as MK-886, was first identified as 
a potent inhibitor of leukotriene biosynthesis in intact leukocytes without 
directly inhibiting 5-LO or phospholipase A2 [155]. MK-886 rather binds to 
the 5-LO activating protein (FLAP) that is needed for 5-LO activity [156] 
thus limiting 5-LO product formation by limiting 5-LOs access to its 
substrate AA with an IC50 of 2.5 nM [157]. In this way FLAP inhibition by 
MK-886 represents a new strategy of leukotriene biosynthesis inhibition 
apart from direct 5-LO suppression [158]. MK-886 shares structural 
similarities with other FLAP inhibitors as licofelone (Fig. XVIII) and MK-
591 (not shown). 
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Fig. XIX Chemical structures of MK-886 and licofelone  
 
Utilizing the high affinity and selectivity of MK-886 towards its target 
FLAP has helped as a pharmacological tool to assess the 5-LO pathway in 
many studies. MK-886 is used as a reference inhibitor for screenings of new 
5-LO inhibitors or to discern the role of 5-LO in certain disorders as cancers 
or inflammatory diseases. However, some additional targets for MK-886 
have been described. It not only affects 5-LO and FLAP but also was 
described to affect leukotriene biosynthesis by interference with leukotriene 
C4 synthase [159]. MK-886 also impairs prostaglandin E2 formation by 
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interference with microsomal PGE2 synthase [160]. Also COX-1 activity 
and platelet aggregation were recently found to be inhibited by MK-886 
[157]. The peroxisome-proliferator-activated receptor α (PPARα) is also 
inhibited by MK-886 [161, 162]. Moreover, for MK-886 actions have been 
described that could not clearly be connected to inhibition of leukotriene 
synthesis. MK-886 also has antiproliferative effects and was found to induce 
apoptosis in various cancer cell lines [163-167], but only in concentrations 
far higher than needed for inhibition of leukotriene biosynthesis (1-50 µM). 
Some of these effects were more importantly found in cells that do not 
express 5-LO [163, 167] indicating a mechanism completely independent 
from 5-LO and pointing to other possible targets of MK-886. Interestingly, 
some other effects apart from enzyme inhibitions were recently identified 
for MK-886. Apparently it influences [Ca2+]i levels in prostate carcinoma 
cells (PC-3) [168] and Madin Darby kidney cells [169]. Effective 
concentrations for [Ca2+]i mobilisation also lay above those needed for 
inhibition of leukotriene biosynthesis with 10-50 µM as was the case for 
induction of apoptosis. Still, as [Ca2+]i is a strong modulator of many 
intracellular functions and proteins, especially in polymorphonucelar 
leukocytes (PMNL) that also express 5-LO, a [Ca2+]i elevating effect of 
MK-886 could have a tremendous impact on cell activity and enzyme 
regulation pathways. In this respect MK-886 should be reassessed in its 
function as a pharmacological tool. 
1.10  Aim of the Study 
p12-LO is the LO that was first discovered in mammals and still only little is 
known about the regulation of activity and about its pharmacological 
intervention. p12-LO is highly expressed and constitutively active in 
platelets. Although a possible function for regulation of platelet activation 
and aggregation was attributed to p12-LO activity and metabolite 12-HETE 
implicating a possibly prominent role for p12-LO in cardiovascular disease, 
a comprehensive pharmacological characterization of p12-LO activity and 
regulation is yet missing and urgently needed. When it became clear that a 
rapid regulation of human 5-LO in PMNL by androgens was responsible for 
a gender bias in inflammatory disease [127], a study of possible regulatory 
effects of sex hormones on p12-LO seemed the most obvious approach for a 
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characterization of p12-LO regulation. Both enzymes share a high homology 
in amino acid structure, both are expressed in cells of the blood lineage 
(leukocytes and platelets) and both are involved in the genesis of diseases 
with a strong gender bias, inflammatory disease for 5-LO and cardiovascular 
disease for p12-LO [126, 128]. In cardiovascular disease, female sex 
hormones are suspected to have a protective benefit. Regulatory influences 
and mechanisms of action of sex hormones have long since been studied; the 
main focus was directed on research of long-term genomic influences 
regarding transcriptional modifications. In the recent years, a different kind 
of influence was discovered: rapid non-genomic actions of sex hormones 
that directly influence intracellular signalling events. For example, on one 
hand androgenic regulation of 5-LO was too rapid to be mediated by 
classical genomic effects although the effect was observed in nucleate cells 
(PMNL) where genomic regulation would at least be possible [127]. 
Platelets on the other hand are anucleate cells, so classical genomic 
influences of sex hormones are not possible. 
The aim of this study was to characterize p12-LO regulation of activity more 
clearly and to characterise its pharmacological inhibitors. First, a possible 
sex difference in regulation was investigated. Influence of human sex 
hormones estradiol, testosterone and progesterone on p12-LO activity in 
intact and cell free systems was determined and possible regulatory 
pathways were elucidated. Secondly, typical pharmacological tools to study 
p12-LO regulation were applied. Thus, the long recognized selective p12-
LO inhibitor CDC and the FLAP inhibitor MK886 that should not influence 
p12-LO activity at all as platelets do not express FLAP were investigated. 
With these approaches a better characterization of p12-LO properties in 
intact cells was within reach and results of these studies are presented in this 
work. 
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2 Materials and Methods 
2.1 Materials 
[3H]AA   BioTrend Chemicals (Köln, Germany), 8-bromo-cAMP   Biomol 
(Plymouth Meeting, PA, USA), AA   Sigma-Aldrich (Deideshofen, Germany), β-
mercaptoethanol   Carl Roth (Karlsruhe, Germany), A23187 (Ca2+-ionophore)   
Sigma-Aldrich (Deideshofen, Germany), CDC   Biomol (Plymouth Meeting, PA, 
USA), COX-1 (ovine)   Cayman Chemical (Ann Arbor, MI, USA), COX-2 (human 
recombinant)   Cayman Chemical (Ann Arbor, MI, USA), cPLA2 inhibitor   
Calbiochem (Bad Soden, Germany), Cyproterone acetate   LKT Laboratories (St. 
Paul, MN, USA), 2,7-Dichlorofluorescin diacetate   Sigma-Aldrich (Deideshofen, 
Germany), Dihydrotestosterone   Sigma-Aldrich (Deideshofen, Germany), DMSO   
Carl Roth (Karlsruhe, Germany), Ethanol   Merck (Darmstadt, Germany), Estradiol   
Sigma-Aldrich (Deideshofen, Germany), Fatty acid-free BSA   Sigma-Aldrich 
(Deideshofen, Germany), Fura-2/AM   Alexis Corp (Lausen, Switzerland), H89   
Cayman Chemical (Ann Arbor, MI, USA), HEPES   Applichem GmbH ( 
Darmstadt, Germany), HybondTM ECL Membrane   GE Healthcare (Munich, 
Germany), Kollagenreagenz Horm®   Nycomed Pharma GmbH (Wien, Austria), 
Methanol   Merck (Darmstadt, Germany), Mifepristone   Cayman Chemical (Ann 
Arbor, MI, USA), MK-886   BioTrend Chemicals (Köln, Germany), LSM 1077 
Lymphocyte Separation Medium   PAA (Coelbe, Germany), Plastic/PS-materials   
Greiner bio-one (Frickenhausen, Germany), PGE2   Cayman Chemical (Ann Arbor, 
MI, USA), peqGold Protein Marker IV   peqLab Biotechnology, (Erlangen, 
Germany), Progesterone   Sigma-Aldrich (Deideshofen, Germany), PMA   Alexis 
Corp (Lausen, Switzerland), SDS   Carl Roth (Karlsruhe, Germany), Thrombin   
Sigma-Aldrich (Deideshofen, Germany), Tween 20   Carl Roth (Karlsruhe, 
Germany), U-46619   Calbiochem (Bad Soden, Germany), Ultima GoldTM XR   
Perkin Elmer (Boston, MA, USA) 
Primary antibodies   Cell Signalling (Boston, MA, USA), secondary antibodies    
Cy-5 labelled GE Healthcare/ Amersham (Munich, Germany),   alkaline 
phosphatase labelled Sigma Aldrich (Deideshofen, Germany) 
 
All other chemicals were purchased in analytical grade from Sigma-Aldrich 
(Deideshofen, Germany) or Applichem GmbH (Darmstadt, Germany) unless stated 
otherwise. 
p12-LO primary antibody was a generous gift of Prof. C. Funk (Queen’s 
University, Kingston Ontario, Canada). 
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2.2 Methods 
2.2.1 Isolation of human platelets from venous blood 
Venous blood from healthy donors was taken and leukocyte concentrates (buffy 
coats) were prepared by centrifugation at 4,000 × g, 20 min, room temperature 
(RT). Buffy coats were diluted 1:1 (v/v) with phosphate buffered saline pH 7.4 
(PBS) and then with ice-cold 5% dextrane (w/v in PBS) in a ratio 1:4 (v/v), for 
sedimentation for 45 min. After dextrane sedimentation cells were immediately 
separated by centrifugation at 1,000 × g, 10 min, RT, w/o brake (Heraeus Sepatech, 
Varifuge 3.0, Hanau, Germany) on LSM 1077 Lymphocyte cushions. Platelets 
were isolated from supernatants after centrifugation of leukocyte concentrates to 
obtain platelet rich plasma (PRP). PRP was then mixed with ice-cold PBS pH 5.9 
(3:2, v/v), centrifuged at 1,000 × g, 10 min, 4°C (Beckman GS-6R Centrifuge, 
Beckman Coulter, Fullerton, CA, USA) and the pelleted platelets were resuspended 
in ice-cold PBS pH 5.9/NaCl 0.9% (1:1, v/v) and washed by centrifugation (1,000 
× g, 10 min, 4°C). Preparation of platelets at pH 5.9 is thought to minimize 
temperature activation. Finally, platelets were resuspended in ice-cold PBS pH 7.4 
buffer containing 1 mg/ml glucose (PG buffer) as specified and kept on ice until 
further use. For assays determining [Ca2+]i platelets were isolated from buffy coats 
as described above but kept at room temperature until Fura-2 loading.  
In experiments investigating platelet aggregation, human platelets were freshly 
isolated from venous blood of healthy donors (Blood Centre, University Hospital 
Tübingen, Germany) who had not taken any medication for at least 10 days. 
Briefly, venous blood was collected in monovettes (Monovette®, Sarstedt, 
Nümbrecht, Germany) containing 0.106 mol/l trisodium citrate solution. PRP was 
obtained after centrifugation of whole blood at 200 × g, 15 min, RT w/o brake and 
placed into 15 ml conical tubes containing 10% (v/v) ACD-buffer (85 mM 
trisodium citrate, 65 mM citric acid, 100 mM glucose) [170]. PRP was centrifuged 
at 800 × g, 10 min, RT, pelleted platelets were washed twice and finally 
resuspended in Tyrode´s buffer (129 mM NaCl, 8.9 mM NaHCO3, 0.8 mM 
KH2PO4, 0.8 mM MgCl2, 5.6 mM glucose, 10 mM N-2-hydroxyethylpiperazine-
N’-2-ethanesulfonic acid (HEPES) pH 7.4, cells were kept at RT at all times.  
2.2.2 Isolation of human polymorphonuclear leukocytes (PMNL) from 
venous blood 
Human polymorphonuclear leukocytes (PMNL) were freshly isolated from buffy 
coats obtained from the Blood Centre, University Hospital Tübingen (Germany). In 
brief, leukocyte concentrates were prepared by centrifugation at 4,000 × g, 20 min, 
RT. Buffy coats were diluted 1:1 (v/v) with ice-cold PBS pH 7.4 and then with ice-
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cold 5% dextrane (w/v in PBS) in a ratio 1:4 (v/v), for sedimentation for 45 min. 
After dextrane sedimentation neutrophils were immediately isolated by 
centrifugation at 1,000 × g, 10 min, RT, w/o brake (Heraeus sepatech, Varifuge 3.0, 
Hanau, Germany) on Lymphoprep cushions, and hypotonic lysis of erythrocytes as 
described [171]. PMNL (1 × 107 cells /ml; purity > 96-97%) were finally 
resuspended in PG buffer. 
2.2.3 Preparation of platelet rich plasma (PRP) and plasma from venous 
blood 
PRP was obtained from venous blood from healthy male and female donors (Blood 
Centre, University Hospital Tübingen, Germany) who had not taken any 
medication for at least 10 days. Briefly, venous blood was collected in monovettes 
(Monovette®, Sarstedt, Nümbrecht, Germany) containing 0.106 mol/l trisodium 
citrate solution. Monovettes were centrifuged at 200 × g, 15 min, RT w/o brake. 
The resulting supernatant (PRP) was used directly for incubations and 
determination of p12-LO and COX-1 activity in PRP. For preparation of plasma 
venous blood from healthy male and female donors (Blood Centre, University 
Hospital Tübingen, Germany) who had not taken any medication for at least 10 
days was collected in monovettes (Monovette®, Sarstedt, Nümbrecht, Germany) 
containing 0.106 mol/l trisodium citrate solution. Monovettes were directly 
centrifuged at 600 × g, 12 min, RT and plasma as resulting supernatant was 
collected. The supernatant was analyzed to confirm the absence of cellular 
contaminations and stored at -20°C until further use [127]. If necessary, hormone 
plasma levels were determined at the Central Lab of Tübingen University 
(Germany). 
2.2.4 Determination of p12-LO and COX-1 product formation in intact 
human platelets 
As p12-LO and COX-1 are the major enzymes in platelets converting AA into 
oxidized metabolites 12-HETE and 12-HHT [86, 172], those AA metabolites were 
used as parameters to determine p12-LO and COX-1 activity. Freshly isolated 
platelets (108/ml in PG buffer) were supplemented with 1 mM CaCl2. Washed 
platelets were pre-incubated with the indicated agents at 37°C for the indicated 
times. Reactions were either terminated directly after the indicated times without 
platelet stimulation to determine spontaneous basal 12-HETE and 12-HHT 
formation or p12-LO and COX-1 product formation was activated by cell 
stimulation with thrombin (1 U/ml), A23187 (1/2.5/3 µM), collagen (8/12 µg/ml) 
or AA (1/3/10 µM) in the indicted concentrations. In this case, the reactions were 
stopped 10 min after addition of stimulus with 1 ml of ice-cold methanol and 30 µl 
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HCl, 200 ng prostaglandin B1 (PGB1, internal standard) and 500 µl PBS were 
added. The p12-LO (12-HETE) and COX-1 (12-HHT) products were extracted and 
then analyzed by HPLC as described [75, 127, 173]. In detail, after centrifugation 
(800 × g, 10 min, RT) samples were applied to C-18 solid-phase extraction 
columns (100 mg; IST, Mid Glamorgan, UK), which had been preconditioned with 
100 % methanol, 25% methanol and water (1ml, each). The columns were washed 
with 1 ml water, 1 ml methanol 25% (v/v) and p12-LO and COX-1 products were 
eluted with 300 µl methanol and then diluted with 120 µl water. 100 µl diluted 
extract was analyzed by HPLC on a Nova-Pak® C18 column (5 × 100 mm, 4 µm 
particle size, Waters (Eschborn, Germany)) using 76% methanol aq. + 0.007% TFA 
(v/v) as mobile phase at a flow rate of 1.2 ml/min and UV detection at 235/280 nm. 
The amount of 12-HETE and 12-HHT was determined by peak area integration. 
p12-LO and COX-1 product formation is expressed as ng of 12-HETE or 12-HHT 
per 108 cells. 
2.2.5 Determination of p12-LO and COX-1 activity in human whole blood 
and PRP 
For assays in whole blood, freshly drawn blood from healthy male and female adult 
donors was obtained by venipuncture and collected in monovettes containing 0.106 
mol/l trisodium citrate solution (Sarstedt, Nümbrecht, Germany). Aliquots of 2 ml 
were pre-incubated with the test compounds or with vehicle for 20 min at 37°C, 
and formation of p12-LO and COX-1 products was started by addition of A23187 
(30 µM). The reaction was stopped on ice and the samples were centrifuged at 600 
× g, 10 min, 4°C (Thermofisher MicromaxRX, Fisher Scientific, Schwerte, 
Germany). Aliquots of the resulting plasma (500 µl) were then mixed with 2 ml of 
methanol and 200 ng PGB1 were added as internal standard. The samples were 
placed at -20°C for 2 h and centrifuged again (600 × g, 15 min, 4°C). The 
supernatants were collected and diluted with 2.5 ml PBS and 75 µl HCl (1M). 
Formed 12-HETE and 12-HHT was extracted and analyzed by HPLC as described 
for intact human platelets in 2.2.4. For analysis of p12-LO and COX-1 activity in 
platelet rich plasma (PRP), PRP was prepared from freshly drawn blood obtained 
from healthy male and female adult donors as described above. PRP was prepared 
by centrifugation of the monovettes as stated in 2.2.3 and the resulting supernatant 
was directly used for incubations. Reactions were stopped by addition of 2 ml 
methanol to 500 µl PRP and further sample preparation was performed as stated 
above for whole blood samples. 
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2.2.6 Determination of p12-LO and COX-1 product formation in platelet 
homogenates 
Freshly isolated washed platelets in PBS buffer containing 1 mM EDTA were 
homogenized by sonification (3 × 20 s, 4°C, Branson Sonifier Cell Disruptor B15, 
Branson , Danbury, CT, USA) in a small volume (1 ml platelet suspension max.). 
Cell rupture was checked under the microscope. Cell homogenates were diluted to 
the desired volume (1 ml corresponding to 108 cells) and were pre-incubated with 
the indicated substances for 10 or 20 min on ice respectively with 2 mM CaCl2 
present. Homogenates were then incubated at 37°C with or without addition of AA 
(0.2/10 µM) as substrate for further 10 min. After 10 min at 37°C the reactions 
were stopped with 1 ml of ice-cold methanol and 30 µl HCl, 200 ng prostaglandin 
B1 ((PGB1), internal standard) and 500 µl PBS were added. The p12-LO (12-
HETE) and COX-1 (12-HHT) products were extracted and then analyzed by HPLC 
as described in 2.2.4. 
2.2.7  Determination of cell-free COX-1/-2 activity 
Inhibition of the activities of isolated ovine COX-1 and human COX-2 was 
performed as described [174, 175]. Though the purified COX-1 is not of human 
origin, ovine COX-1 is generally used for inhibitor studies when examining the 
effectiveness of compounds on the activity of isolated COX-1 enzyme [175]. 
Briefly, purified COX-1 (ovine, 50 units) or COX-2 (human recombinant, 20 units) 
were diluted in 1 ml reaction mixture containing 100 mM Tris buffer pH 8.5 mM 
GSH, 5 µM haemoglobin, 100 µM EDTA at 4°C and pre-incubated with the test 
compounds for 5 min. Samples were pre-warmed for 60 s at 37°C and AA (5 µM 
for COX-1 and 2 µM for COX-2) was added to start the reaction for additional 5 
min at 37 °C. Reactions were stopped with 1 ml of ice-cold methanol and 30 µl 
HCl, 200 ng prostaglandin B1 ((PGB1), internal standard) and 500 µl PBS were 
added and COX product 12-HHT was extracted and then analyzed by HPLC as 
described in 2.2.4 [75, 173]. The amount of 12-HHT was determined by peak area 
integration. COX-1/2 product formation is expressed as % rest activity of solvent 
control. 
2.2.8 Determination of TXB2-levels in human platelets 
To assess stimulus-induced TXB2 formation, freshly isolated platelets (108/ml in 
PG buffer) were pre-incubated with the indicated compounds for 20 min at 37°C 
before stimulation with thrombin (1 U/ml), A23718 (3 µM), collagen (8 µg/ml) or 
AA (3 µM) and further incubation for 10 min at 37°C. After 10 min, reactions were 
stopped on ice, cells were centrifuged at 1,000 × g, 10 min, 4°C (Beckman GS-6R, 
Beckman Coulter, Fullerton, CA, USA) and TXB2 was quantified in the resulting 
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supernatants using a TXB2 High Sensitivity EIA Kit (Assay Designs, Ann Arbor, 
MI) according to the manufacturer's protocol. 
2.2.9 Determination of AA release in human platelets and cell-free cPLA2 
activity 
Human PRP was labelled with 19.2 nM [3H] AA (1 µCi/ml, specific activity 200 
Ci/mmol) for 2 hours at 37°C. Then, cells were washed twice with PBS pH 5.9 plus 
1 mM MgCl2, 11.5 mM NaHCO3, 1 mg/ml glucose, and 1 mg/ml fatty acid-free 
BSA. Platelets were finally resuspended in PGC buffer (108/ml) and subsequently 
stimulated with thrombin (1 U/ml) or A23187 (2.5 µM) for 5 min at 37°C and then 
put on ice for 10 min, followed by centrifugation (5,000 × g, 15 min). Aliquots 
(300 µl) of the supernatants were mixed with 2 mL of Ultima GoldTM XR and 
measured (Micro Beta Trilux, Perkin Elmer) to detect the amounts of [3H]-labelled 
AA released into the medium. [176]. To measure AA release over long incubation 
times, a method for AA derivatization was applied. In short, freshly isolated human 
platelets (108/ml cells in PG buffer) were supplemented with the p12-LO inhibitor 
CDC (15 µM) to avoid the conversion of released AA to LO and COX-1 
metabolites. The reaction was started by addition of the indicated test compounds 
for 30 to 120 min. Reactions were either terminated after the indicated incubation 
times or cells were stimulated with A23187 (2.5 µM). After 5 min at 37°C, the 
reaction was stopped by addition of 2 ml methanol. After adjusting pH 3 and 
addition of magarinic acid (11.1 nmol) as internal standard, released AA was 
separated by solid phase extraction (RP-18 material and elution with methanol) and 
coupled to 2,4-dimethoxyaniline hydrochloride (0.14 mg, 0.75 µmol) using N-
Ethyl-N'-(3-dimethylaminopropyl)carbodiimide (1.46 mg, 9.4 µmol) as coupling 
reagent for 1 h at 37°C. Derivatized AA was analyzed by RP-HPLC (gradient: 71% 
methanol / 29% water to 100% methanol in 20 min, detection at 272 nm). Amounts 
of released AA were determined by comparison of peak areas to standard 
(margarinic acid) and were expressed in % release of standard [127]. To determine 
the activity of cell-free cPLA2 recombinant cPLA2 was expressed in SF-9 cells and 
purified by affinity chromatography. Vesicle solutions were prepared freshly for 
each assay: In detail, 50 nmol lipids (i.e. a mixture of PAPC (= 1-Palmitoyl-2-
Arachidonyl-sn-Glycero-3-Phosphocholine) and POG (= 1-Palmitoyl-2-Oleoyl-sn-
Glycerol) 2:1) were dried completely under nitrogen at continuous rotation. 190 µl 
of vesicle buffer (20 mM Tris pH 7.4, 134 mM NaCl, 1 mg/ml fatty acid free-BSA) 
were added. To disperse the lipids homogenously, the mixture was put through 2-3 
freeze-thaw cycles (N2 liq./ 37°C) and the solution was extruded 11 times through a 
polycarbonate membrane (pore size 100 nm) to form LUV (large unilamellar 
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vesicles). For each sample 190 µl of vesicle solution was used. The enzyme 
solution contained 500 ng/µl purified cPLA2 in TNG buffer (10 mM Tris pH 8.0, 
300 mM NaCl, 20 % Glycerol) diluted 1:10 (v/v). For the assay, to 190 µl vesicle 
solution, 1mM EDTA or 1 mM CaCl2, the respective substances and 10 µl of 
enzyme solution were added. The mixture was incubated for 60 min at 37°C. 
Reaction was stopped with 1.6 ml of methanol, and 1 nmol γ-linolenic acid 
(internal standard), 40 µl HCl (1N) and 1.6 ml PBS were added. Released AA was 
separated by solid phase extraction (RP-18 material and elution with methanol), 
derivatized with p-anisidinium chloride (Merck) and analyzed by HPLC as 
described above with detection at 250 nm. 
2.2.10 Determination of reversibility of inhibition 
Washed human platelets (108/ml in PG buffer) were incubated with the indicated 
compounds for 30 min. Reactions were stopped on ice and cells were centrifuged at 
1,000 × g, 10 min, 4°C (Beckman GS-6R, Beckman Coulter, Fullerton, CA, USA). 
Buffer was removed and replaced by PG buffer containing BSA fatty acid free 1 
mg/ml (PG-BSA buffer) in half the samples to bind the examined substances and 
remove them from the cell sample. The other half was used as control samples 
where no buffer exchange was performed, although they were centrifuged in the 
same way as the washed samples. Cells were resuspended in the respective buffers, 
centrifuged again at the same conditions, and PG-BSA buffer was removed and 
replaced with fresh PG buffer. Cells were incubated for another 30 min and 
reactions were terminated by addition of 1 ml methanol. p12-LO and COX-1 
products were extracted and analyzed by RP-HPLC as described in 2.2.4.  
2.2.11 Determination of p12-LO translocation 
Freshly isolated human platelets (1 × 109/ml in PG buffer) were supplemented with 
CaCl2 1 mM and aliquoted (1 ml) to 1.5 ml Eppendorf cups. Samples were pre-
warmed at 37°C for 5 min on the heating block. To determine the influence of the 
indicated substances on p12-LO translocation and induction of p12-LO 
translocation, the indicated substances were added after pre-warming and cells 
were incubated for further 30 min. Then reactions were either stopped or stimulated 
with thrombin 1 U/ml to induce translocation. To determine subcellular localisation 
after stimulation with p12-LO activators, platelets were stimulated for 10 min at 
37°C with thrombin 1 U/ml or collagen 12 µg/ml after pre-warming. Reactions in 
both cases were stopped by putting Eppendorf cups into liquid nitrogen. Cells were 
lysed by repeated freeze-thaw cycles (3 ×), cell rupture was checked under the 
microscope. Aliquots of 300 µl of the cell homogenates were centrifuged at 
100.000 × g, 1h, 4°C, (Beckman L7-65 Ultracentrifuge, Beckman Coulter, 
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Fullerton, CA, USA) to prepare soluble (S100) and pelletable (P100) fractions [95, 
98]. After centrifugation 200 µl supernatant (= S100) were mixed with 150 µl 2 × 
SDS loading buffer (SDS-LB) and boiled for 5 min at 96°C. The remaining 
supernatant was discarded, the pellet (= P100) was rinsed once with PG buffer and 
resuspended in 300 µl PG buffer. The pellet suspension was sonified (1 × 10 sec on 
ice) to fully disperse membrane aggregates. 200 µl of the pellet solution was mixed 
with 150 µl SDS-LB and boiled for 5 min at 96°C. Samples were stored at -20°C 
until separation by SDS-PAGE followed by WB using specific antibodies (2.2.18 
and 2.2.19). 
2.2.12 Platelet aggregation (turbidimetric) 
Aggregation of washed human platelets was determined using a turbidimetric light-
transmittance device (two channel Chrono-Log aggregometer, Haverton, PA, USA) 
as described [157]. In short, washed human platelets were prepared as described in 
2.2.1 and adjusted to 2 × 108/ml. The instrument was calibrated with a platelet 
suspension for basal (0%) light transmission and with Tyrode`s buffer alone for 
100% light transmission. Aliquots of 0.5 ml platelets were incubated with the 
indicated substances for 0-120 min at RT. For aggregation, the response to 1 U/ml 
thrombin, 1 µg/ml collagen, 1 µM U-46619 or 200 µM AA is given as % of the 
maximal light transmission Amax. CaCl2 (1 mM) was added right before the start of 
the measurement. Aggregation was recorded under continuous stirring (1000 rpm) 
at 37°C for 5 min. 
2.2.13 Measurement of intracellular [Ca2+]i levels in platelets and PMNL 
Washed human platelets (6 × 108/ml PG buffer) were incubated with 2 µM Fura-
2/AM (1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2'-amino-5'-
methyl-phenoxy) ethane-N,N,N',N'-tetraacetic acid) for 40 min at 37°C. After 
washing platelets (108/ml in PG buffer) were directly transferred into a thermally 
controlled (37°C) fluorimeter cuvette in a spectrofluorometer (Aminco-Bowman 
series 2, Thermo Spectronic, Rochester, NY) with continuous stirring. One min 
prior addition of the indicated substances 1 mM CaCl2 was added. The fluorescence 
emission at 510 nm was measured after excitation at 340 and 380 nm, respectively, 
and [Ca2+]i was calculated according to Grynkiewicz et al. [177]. Fmax (maximal 
fluorescence) was obtained by lysing the cells with 1% Triton-X 100 and Fmin by 
chelating Ca2+ with 10 mM EDTA. For samples where a long-time influence of 
substances on [Ca2+]i levels was determined platelets were pre-incubated with the 
indicated agents for 20, 30, 60 or 120 min at 37°C after Fura-2 loading and 
washing. Cells were transferred to a thermally controlled (37 °C) fluorimeter 
cuvette in a spectrofluorometer as described and were stimulated with thrombin 1 
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U/ml or collagen 12 µg/ml 30 s after start of measurement. [Ca2+]i was determined 
as described above. Determination of [Ca2+]i levels in PMNL was performed as 
described previously [171]. In short, for measurement of [Ca2+]i mobilization in 
PMNL washed human PMNL (6 × 108/ml PG buffer) were incubated with 2 µM 
Fura-2/AM (1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2'-amino-
5'-methyl-phenoxy) ethane-N,N,N',N'-tetraacetic acid) for 40 min at 37°C. After 
washing PMNL (106/ml in PG buffer) were directly transferred into a thermally 
controlled (37°C) fluorimeter cuvette in a spectrofluorometer (Aminco-Bowman 
series 2, Thermo Spectronic, Rochester, NY) with continuous stirring. One min 
prior addition of the indicated substances 1 mM CaCl2 was added and [Ca2+]i 
mobilization was measured as stated above. 
2.2.14 Measurement of ROS formation in human platelets  
Measurement of peroxides was conducted using the peroxide-sensitive fluorescence 
dye DCF-DA. Freshly isolated platelets (108/ml in PG buffer) were pre-incubated 
with the indicated substances for 20 min at 37°C. After 20 min cells were pre-
incubated with DCF-DA (1 µg/ml) for 2 min at 37°C in a thermally controlled 
(37°C) fluorimeter cuvette in a spectrofluorometer (Aminco-Bowman series 2, 
Thermo Spectronic, Rochester, NY, USA) with continuous stirring. The 
fluorescence emission at 530 nm was measured after excitation at 485 nm. The 
mean fluorescence data measured 5 min after stimulus addition are given as 
arbitrary units [178]. 
2.2.15 Determination of kinase phosphorylation status 
Human platelets were obtained as described (2.2.1) and adjusted to 1 × 109/ml in 
PG buffer. Cells were supplemented with CaCl2 1 mM and incubated with 
progesterone or vehicle control for 0-120 min at 37°C. After the indicated times the 
reaction was terminated by adding a half-volume of 2 × SDS-LB and boiled at 
95°C for 5 min. Samples were stored at -20°C until separation by SDS-PAGE 
followed by WB using specific antibodies (2.2.18 and 2.2.19). Control samples 
were supplemented with CaCl2 1 mM and stimulated with thrombin (1 U/ml), 
collagen (12 µg/ml) or PMA (100 nM) for 7 min at 37°C (positive controls) or left 
resting on ice without CaCl2 addition (negative controls). Reactions were 
terminated as described above and samples were stored at -20°C until separation by 
SDS-PAGE followed by WB using specific antibodies (2.2.18 and 2.2.19). 
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2.2.16 Sample preparation for p12-LO protein amount determination and 
progesterone receptor blots 
Suspensions of freshly isolated washed platelets (5 × 108/ml in PG buffer) or PC-3 
cells (1 × 106/ml, see 2.2.17) were lysed by addition of ice-cold 2 × SDS-LB 1:1 
(v/v). Samples were heated at 96°C for 5 min and stored at -20°C until SDS-PAGE 
and Western Blot analysis (2.2.18 and 2.2.19). 
2.2.17 Cell culture of PC-3 cells 
Human prostate cancer cell line PC-3 was used as a control for the progesterone 
receptor in Western blot analysis. In short, PC-3 cells were grown in PC-3 medium 
(RPMI + 5% Penicillin/ Streptomycin + 2 mM Glutamate + 10% FCS) to 70% 
confluency. The cells were harvested and diluted in SDS loading buffer to a density 
of. Protein samples were prepared for Western Blot as described in 2.2.16 and 
stored at -20°C until SDS-PAGE and Western Blot analysis (2.2.18 and 2.2.19). 
2.2.18 SDS-PAGE 
Cell suspensions or given sample preparations were incubated as specified and the 
reaction was stopped by the addition of ice-cold 2 × SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) sample loading buffer (SDS-LB; 20 mM Tris/HCl, 
pH 8, 2 mM EDTA, 5% SDS (w/v), 10% (v/v) β-mercaptoethanol), vortexed, 
sonificated (3 × 15 s) if required and heated for 5 min at 95 °C. The protein samples 
(18 µl) were mixed with 4 µl of glycerol/0.1% bromophenolblue (1:1, v/v) and 
analyzed by SDS-PAGE using a Mini Protean system (Bio-Rad, Hercules, CA, 
USA) according to Laemmli [179]. Depending on the molecular weight of the 
proteins to be analyzed, the polyacrylamid (PAA) concentration was adjusted to 8% 
(progesterone receptor) or 10% (p12-LO translocation, p12-LO protein expression, 
kinase phosphorylation assay). Molecular weight of the proteins was estimated by 
comparison with prestained broad range molecular weight marker peqGOLD IV 
(peqLab Biotchenology, Erlangen Germany). 
2.2.19 Western Blot 
After electroblot (tank blotting method) of gels from SDS-PAGE to nitrocellulose 
membrane (Amersham Pharmacia, Little Chalfont, UK), membranes were blocked 
with 5% (w/v) BSA blocking buffer (50 mM Tris/HCl, pH 7.4, and 100 mM NaCl 
(Tris-buffered saline (TBS)) plus 0.1% Tween 20 (TBS-Tween)) for 1 h at RT. 
Correct loading of the gel and transfer of proteins to the nitrocellulose membrane 
was confirmed by Ponceau S staining. Membranes were washed (TBS-Tween) and 
then incubated with the respective primary antibody (AB) overnight at 4°C (Table 
I). Antibodies were diluted in TBS Tween, 0.05% NaN3 (v/v), 5% milk or BSA as 
indicated. The membranes were washed and incubated with 1:1000 dilution of 
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secondary AB (Cy-5 conjugated IgGs or alkaline peroxidase-conjugated IgGs) for 1 
or 3 h at RT. After washing (4 × with TBS-Tween and TBS), proteins were 
visualized with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate in 
detection buffer (100 mM Tris/HCl, pH 9.5; 100 mM NaCl, 5 mM MgCl2) or 
analyzed by fluorescence detection (Ettan DIGE). All steps regarding the 
incubation of the membrane were performed under gentle agitation.  
 
Primary antibody Isotype Dilution Company 
  p12-LO Rabbit IgG 1:500 Gift of C.Funk 
  pERK Mouse IgG 1:1000 Cell Signalling 
  pp38 Rabbit IgG 1:1000 Cell Signalling 
  pAkt Rabbit IgG 1:1000 Cell Signalling 
  pMARCKS Rabbit IgG 1:1000 Cell Signalling 
  Progesterone 
  receptor 
Mouse IgG 1:1000 Santa Cruz 
Table I. Primary antibodies 
 
2.2.20 Statistics 
Data are expressed as mean ± S.E.; IC50 and EC50 values are approximations 
determined by graphical analysis (linear interpolation between the points 
neighbouring 50% activity). Statistical evaluation of the data was performed by 
one-way ANOVA tests for independent or correlated samples followed by 
Bonferroni post-hoc tests (GraphPad Software Inc.). Where appropriate, Student´s t 
test for paired and correlated samples was applied. A p value of < 0.05 (*) was 
considered significant. 
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3 Results 
3.1 p12-LO and gender influence on p12-LO activity 
As leukotriene biosynthesis was found to be differentially regulated in male 
and female neutrophils [127], a possible gender influence on the regulation 
of p12-LO product formation was investigated in human platelets. To this 
aim, the p12-LO pathway was analysed at different levels, as protein 
expression, cell-free and cellular activity, subcellular localisation and 
substrate availability. 
3.1.1 Determination of p12-LO activity in washed platelets 
To evaluate the influence of gender on spontaneous cellular p12-LO product 
formation freshly isolated washed platelets from male and female donors 
were incubated at 37°C in PG buffer for different time periods, without cell 
stimulation. No difference in 12-HETE formation was found between cells 
isolated from male and female donors (Fig. 1.1). 
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Fig. 1.1 Spontaneous p12-LO product formation in human platelets Washed 
human platelets (108 /ml in PG buffer) isolated from male and female donors were 
incubated at 37°C for the indicated times. CaCl2 (1 mM) was added 50 s before 
start of the incubation. The reaction was terminated with 1 ml methanol and 
samples were extracted and analysed by RP-HPLC. Data are given as mean 
ng/108 cells ± S.E. (n = 6). 
 
Next, cells were stimulated with different cell activating agents, as platelet 
specific and physiopathologically relevant activators (thrombin and 
collagen), with the p12-LO substrate arachidonic acid (AA) or other well-
recognized stimulatory agents (i.e., A23187). No significant differences 
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were observed between p12-LO activities in male and female platelets under 
these conditions (Fig. 1.2). 
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Fig. 1.2 p12-LO product formation in stimulated human platelets Washed 
human platelets (108 / ml PG buffer) isolated from male and female donors were 
stimulated with thrombin (TR, 1 U/ml), A23187 (IO, 1 µM), AA (1 µM) or collagen 
(Coll, 12 µg/ml), after pre-warming for 1 min. CaCl2 (1 mM) was added 50 s prior 
stimulation. Reactions were terminated after 10 min and samples were extracted 
and analyzed via RP-HPLC. Data are given as mean ng/108 cells + S.E. (n = 3) 
3.1.2 Determination of p12-LO activity in platelet rich plasma 
(PRP) from male and female donors 
Washed platelets are no longer in contact with any plasma components (e.g., 
sex hormones) that could be necessary for differential regulation of p12-LO 
between male and female donors. Thus platelet rich plasma (PRP) was used 
to investigate 12-HETE formation under more physiological conditions 
including plasma components. However, 12-HETE formation in PRP did not 
significantly differ between male and female donors, whether basal p12-LO 
activity was measured for 15 or 120 min at 37°C (Fig. 2.1 A) or whether 
cells were stimulated for 10 min with thrombin, collagen, A23187 or AA 
after a preincubation period of 15 minutes (Fig. 2.1 B). 
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Fig. 2.1 Spontaneous and stimulated p12-LO product formation in human 
PRP from male and female donors PRP prepared from freshly drawn venous 
citrate blood from male and female donors was incubated at 37°C (A) for 15 and 
120 min without stimulation or (B) stimulated for 10 min at 37 °C with A23187 (IO 
30 µM), AA (100 µM), thrombin (TR 1 U/0.5 ml) or collagen (Coll 8 µg/ 0.5 ml), after 
a short preincubation time of 15 min. CaCl2 (2 mM) was added to provide adequate 
concentrations when preincubation was started. Reactions were stopped by 
addition of 2 ml methanol and samples were analyzed via RP-HPLC. Data are 
given as mean ng/ 5 × 108 platelets + S.E. (n = 5) and have been normalized to 
represent 5 × 108 cells, as cell numbers varied strongly between donors. 
 
When PRP was stimulated with a combination of A23187 and AA, female 
cells produced more 12-HETE than male cells (Fig. 2.2). However, the 
differences were considered not significant. 
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Fig. 2.2 p12-LO product formation in PRP from male and female donors 
stimulated with A23187 and AA PRP isolated from freshly drawn venous blood 
was stimulated with a combination of A23187 (IO 30 µM) and AA (100 µM) after a 
short preincubation time of 15 min. CaCl2 (1 mM) was added at the start of 
preincubation. Reactions were stopped after 10 min by addition of 2 ml methanol 
and samples were analyzed via RP-HPLC. Data are given an mean ng/ 5 × 108 
platelets + S.E. (n = 5) and have been normalized to represent 5 × 108 cells, as cell 
numbers strongly varied between donors. 
3.1.3 Determination of p12-LO product formation in platelet 
homogenates 
Platelet homogenates prepared from male and female cells were kept non-
stimulated on ice or incubated for 10 min at 37°C in presence of 0.2 µM 
exogenous AA. No difference in p12-LO product formation between male 
and female cell homogenates could be observed (Fig. 3). Interestingly, small 
amounts of 12-HETE were measured also when no AA was added and 
homogenates were kept on ice. 
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Fig. 3 12-HETE production in homogenates from male and female cells Cell 
homogenates from washed human platelets (corresponding to 108/ml in PBS-
EDTA) were prepared by sonification. Cell rupture was checked under the 
microscope. Homogenates were kept on ice or incubated at 37°C with exogenous 
AA (AA 0.2 µM) for 10 min. CaCl2 (2 mM) was added 50 s before AA addition. 
Reactions were stopped after 10 min with 1 ml methanol and samples were 
extracted and analyzed via RP-HPLC. Data are given as mean ng/108 cells + S.E. 
(n = 3). 
3.1.4 p12-LO protein expression in male and female platelets  
To determine the expression of p12-LO in male and female platelets, cells 
from both genders were diluted to the same cell numbers, lysed and 
analyzed via Western Blot. p12-LO was detected by a specific p12-LO 
antibody. The amounts of p12-LO protein were equal in male and female 
cells (Fig. 4). 
 
M        F        M       F         M        F        M       F 
 
Fig. 4 p12-LO protein amounts in platelets from male and female donors 
Washed human platelets (5 × 108/ ml in PG buffer) were lysed by addition of SDS-
loading buffer. Proteins were separated by SDS-PAGE and Western blot analysis 
was performed. Data shown represents at least n = 3 different experiments. 
Ponceau staining of the blotted membranes was used as a loading control (not 
shown). 
3.1.5 Subcellular localisation of p12-LO in male and female 
platelets 
Subcellular localisation of p12-LO was assessed in male and female platelets 
as translocation is considered a necessary step for p12-LO to access its 
substrate AA [98]. Surprisingly, p12-LO was predominately found to be 
localized in the pelletable fraction even without platelet stimulation (Fig. 5 
A). 
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Fig. 5 Subcellular localisation of p12-LO in resting and stimulated cells 
Washed human platelets (1 × 109/ml in PG buffer) were pre-warmed for 5 min at 
37°C with CaCl2 (1 mM) added, stimulated with thrombin (TR 1 U/ml) or collagen 
(Coll 12 µg/ml) for 10 min or left non-stimulated. p12-LO localisation is shown for 
(A) membrane fraction (P100) and (B) cytosolic fraction (S100). As control (ctr) 
cells resting on ice with no CaCl2 supplementation were used. Reactions were 
stopped by freezing samples in N2 liq., cells were lysed by repeated freeze-thawing 
cycles. S100 and P100 fractions were prepared by centrifugation at 100,000 × g, 1 
h, 4°C. Samples were analyzed via SDS-PAGE and Western Blot (Ettan Dige). 
Data shown are representative for n =3 individual experiments. 
 
A constant localisation of p12-LO at the plasma membrane was found 
consistent with a basal p12-LO activity that was observed in non-stimulated 
platelets (Fig. 1.1). However, when the cytosolic fraction was analysed, p12-
LO was found to translocate from the cytosol in the same manner in male 
and female cells (Fig. 5 B). Translocation from the cytosolic fraction could 
be induced in both genders upon stimulation with thrombin (1 U/ml) and 
collagen (12 µg/ml). A slight translocation from the cytosol in comparison 
to the control sample could be detected even in non-stimulated cells that 
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were incubated for 10 min at 37°C with CaCl2 (1 mM) present (Fig. 5 B). 
No increase of p12-LO in the pelletable fraction after stimulation could be 
detected although p12-LO obviously moved from the cytosol, neither via 
calculation of optical densities of protein bands in comparison to the control 
sample nor by visual inspection of Western Blot membranes. 
3.1.6 AA release in male and female platelets 
The release of AA did not significantly differ between male and female 
cells, regardless cell-stimulation (spontaneous release or A23187) or 
incubation time (30, 60 and 120 min) (Fig. 6 A, Fig. 6 B). 
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Fig. 6 AA release in intact human platelets from male and female donors 
Washed human platelets (108/ml in PG buffer) from male and female donors were 
incubated for (A) the indicated times and reactions stopped directly or were (B) 
incubated for 30 min and stimulated for 5 min with A23187 (2.5 µM) for 5 more 
min. CaCl2 (1 mM) and CDC (15 µM, a 12-LO inhibitor) were added to the 
samples shortly before the incubation. Reactions were stopped with 2 ml 
methanol. Released AA was derivatized with a mixture of EDC-dimethoxy aniline 
for 1 h and samples were directly analysed by RP-HPLC analysis. Data are given 
as mean % AA of standard (30 µg/ml margarinic acid) + S.E. (n = 3) *p < 0.05 
paired t-test. 
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3.1.7 Determination of COX-1 product formation in washed 
platelets and PRP 
Besides p12-LO, a major AA-metabolizing pathway in human platelets is 
represented by COX-1. Spontaneous formation of 12-HHT at different times 
(Fig. 7.1 A) as well as agonist stimulated 12-HHT formation (Fig. 7.1 B), as 
measure of COX-1 activity, was found to be the same in male and female 
washed platelets (Fig. 7.1). 
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Fig. 7.1 COX-1 product formation in isolated human platelets from male 
and female donors Washed platelets (108/ml in PG buffer) from male and 
female donors were (A) incubated for 15 and 120 min without stimulus or (B) 
stimulated with thrombin (TR 1U/ml), A23187 (IO 1 µM) AA (1 µM) or collagen 
(Coll. 12 µg/ml) for 10 min. CaCl2 1 mM was added 50 s prior to start of the 
incubation. Reactions were stopped by addition of 1 ml methanol and samples 
were analyzed by RP-HPLC. COX-1 product formation is given as amount of 
12-HHT as stable COX-1 metabolite in mean ng/108 cells + S.E. (n = 3). 
 
PRP prepared from freshly drawn venous blood was used to determine basal 
and stimulated COX-1 activity in more physiological conditions. No 
difference between male and female cells was found for both basal or 
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A23187-, AA-, thrombin- or collagen-stimulated 12-HHT formation (Fig. 
7.2). 
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Fig. 7.2 COX-1 product formation in human PRP from male and female donors 
PRP freshly isolated from male and female donors was incubated at 37°C for 15 or 
120 min. After 15 min PRP was either stimulated with A23187 (IO 30 µM), AA (AA 
100 µM), thrombin (TR 1 U/0.5 ml), collagen (Coll 8 µg/0.5 ml) or a combination of 
A23187 and AA, respectively, for 10 min or reactions were stopped directly after 15 
min without stimulation. Also basal 12-HHT formation after 120 min was 
determined. Reactions were terminated by addition of 2 ml methanol and samples 
were analyzed by RP-HPLC (n = 5). COX-1 product formation is given as amount 
12-HHT as stable COX-1 metabolite in mean ng/ 5 × 108 cells +S.E. Values have 
been calculated to represent 5 × 108 cells as cell numbers varied strongly between 
donors. 
3.2 Effects of progesterone on p12-LO activity 
So far, no difference in p12-LO activity between male and female cells 
could be observed. Nevertheless, most investigations were performed in 
absence of naturally occurring sex hormones and other plasma components, 
so replacement of sex hormones as well as studies of p12-LO function in 
plasma and PRP samples were the next steps. 
3.2.1 Spontaneous 12-HETE formation in washed platelets 
treated with sex hormones 
The effect of sex hormones on spontaneous 12-HETE formation in washed 
platelets was analysed. Under these conditions, 1 µM progesterone 
completely suppressed spontaneous 12-HETE production, whereas no 
effects were observed for 0.1 µM estradiol or 0.01 µM dihydrotestosterone 
(DHT). The effect of progesterone was observed in male as well as in 
female cells (Fig. 8) over long time periods, being most prominent after 120 
minutes preincubation in comparison to vehicle controls. 
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Fig. 8 Effects of sex hormones on p12-LO product formation in isolated 
human platelets from male and female donors Washed human platelets (108/ml 
in PG buffer) from (A) male and (B) female donors were incubated for the indicated 
times at 37°C with ethanol 0.1% as solvent control (ctr), estradiol (0.1 µM), 
dihydrotestosterone (DHT 0.01 µM) or progesterone (1 µM) respectively. CaCl2 (1 
mM) was added directly before sex hormone addition. Reactions were terminated 
by addition of 1 ml methanol and samples were extracted and analyzed by RP-
HPLC. Data are given as mean ng/108 cells +/- S.E. (n = 3 - 6).*p< 0.05, **p < 0.01, 
***p < 0.001 vs. solvent control, ANOVA + Bonferroni post hoc tests. 
3.2.2 12-HETE formation in stimulated washed platelets treated 
with sex hormones 
Next, the effect of sex hormones on stimulated 12-HETE formation was 
analysed. Progesterone, but not estradiol or DHT, significantly impaired 
collagen-induced p12-LO product formation. Progesterone prevented the 
increase of product formation by collagen stimulation by about 50% at a 
concentration of 1 µM (Fig. 9.1). This influence of progesterone on 
collagen-induced 12-HETE production was already observed after 15 min 
pre-incubation (data not shown). Collagen stimulation of p12-LO activity 
was also influenced by very low concentrations of progesterone (0.1 and 0.3 
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µM), when a pre-incubation of 60 min with the hormone prior collagen 
stimulation was performed (Fig. 9.1). 
progesterone [µM]
ctr 0.1 0.3 1 3 10 
12
-
H
ET
E 
(n
g/
10
8  
c
el
ls
)
0
20
40
60
80
100
120
***
* *
 
Fig. 9.1 p12-LO product formation in collagen stimulated platelets 
supplemented with progesterone Washed human platelets (108/ml in PG buffer) 
from female donors were for 60 min at 37°C with the indicated concentrations of 
progesterone. After pre-incubation platelets were stimulated with collagen 12 µg/ml 
for 10 min. CaCl2 (1 mM) was added before hormone supplementation. As solvent 
control (ctr) 0.1% ethanol was used. Reactions were stopped with 1 ml methanol 
and samples were analyzed via RP-HPLC. Data are given as mean ng/108 cells + 
S.E. (n = 3).***p< 0.0007 vs. solvent control, unpaired t-test. 
 
On the contrary, progesterone did not significantly influence thrombin, 
A23187 or AA stimulated 12-HETE formation at concentrations of 1 or 3 
µM (Fig. 9.2). 
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Fig. 9.2 p12-LO product formation in stimulated human platelets 
supplemented with sex hormones Washed human platelets (108/ml in PG buffer) 
from female donors were incubated for 120 minutes at 37°C with estradiol (Est 0.1 
µM), DHT (0.01 µM) and progesterone (Prog 1 and 3 µM) respectively. CaCl2 (1 
mM) was added shortly before hormone supplementation. After 120 min platelets 
were stimulated with (A) collagen (12 µg/ml), (B) thrombin (1 U/ml), (C) A23187 (1 
µM) or (D) AA (1 µM) for 10 min. As solvent control 0.1% ethanol was used (ctr). 
Reactions were stopped with 1 ml methanol and samples were analyzed via RP-
HPLC. Data are given as mean ng/108 cells + S.E. (n = 3) **p < 0.045 ***p < 0.0003 
unpaired t-test vs. solvent control 
 
However, when platelets were incubated with supra-physiological 
concentrations of progesterone (10 µM), a reduction of A23187- and AA- 
stimulated cellular p12-LO activity was observed (Fig. 9.3 A), although 
being not significant. A strong and very significant inhibition of p12-LO 
product formation by 10 µM progesterone was instead observed when the 
thrombin or collagen were used as stimuli. This effect was observed in 
female (Fig. 9.3 B) as well as in male cells (data not shown). 
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Fig. 9.3 p12-LO product formation in stimulated human platelets incubated 
with high progesterone concentrations Washed human platelets (108/ml in PG 
buffer)from  female donors were incubated at 37°C for 120 minutes with 
progesterone 10 µM. After 120 min, platelets were stimulated with (A) A23187 (IO 
1 µM) or AA (AA 1 µM) or (B) thrombin (TR 1 U/ml) or collagen (Coll 12 µg/ml) for 
10 min. Reactions were stopped with 1 ml methanol and samples analyzed via RP-
HPLC. Data are given as mean ng/108 cells + S.E. (n = 3) Data are given as mean 
ng/108 cells + S.E. (n = 3). ***p < 0.0001 vs. solvent control, unpaired t-tests vs. 
olvent control 
 
Importantly, the effect of progesterone was selective for p12-LO, since 
COX-1 product formation was not influenced by progesterone at any 
concentration in non-stimulated (Fig. 9.4) as well as in stimulated cells (data 
not shown) 
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Fig. 9.4 COX-1 activity in resting platelets treated with different progesterone 
concentrations Washed platelets (108/ml in PG buffer) from male and female 
donors were incubated for 60 min without stimulus. CaCl2 1 mM was added 50 s. 
prior to start of the incubation. As solvent control (ctr) 0.1% ethanol was used. 
Reactions were stopped by addition of 1 ml methanol and samples were analyzed 
by RP-HPLC. COX-1 product formation is given as amount 12-HHT as stable COX-
1 metabolite in mean ng /ml + S.E. (n = 3). 
3.2.3 p12-LO activity in female platelets resuspended in plasma 
from male and female donors 
To verify the effects of progesterone on p12-LO product formation under 
more physiologically relevant conditions, platelets were resuspended in 
plasma from male or female donors. Plasma levels of sex hormones 
(testosterone, progesterone and estradiol) in the donors’ blood had been 
measured immediately after the blood was drawn. Mean values for the 
investigated sex hormones determined of all study donors are shown in 
Table1.  
Gender Progesterone Estradiol DHT 
male 2.89 (+/- 0.23) 0.16 (+/- 18,63) 21.09 (+/-1.85) 
female 13.47 (+/-6,78) 0.37 (+/- 80.48 2,06 (+/- 0.20) 
Table 1 Mean hormone plasma levels (nmol/l) +/- S:E: 
 
Cells resuspended in a selected male plasma sample (progesterone 
concentration 4.2 nM) produced more 12-HETE than cells resuspended in 
selected female plasma (progesterone 68 nM) (Fig. 10.1 A). Analysis of 12-
HHT levels in the same samples showed some gender differences, but a 
clear pattern was not evident. These preliminary evidences suggested that 
unrecognized additional factors present in the plasma might have multiple 
effects on different levels of the AA pathways in platelets (Fig. 10.1 B).  
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Fig. 10.1 p12-LO and COX-1 activity in human platelets resuspended in 
male and female plasma with different progesterone levels Washed human 
platelets (approx. 5 × 108/0.5 ml) from female donors were resuspended in 
plasma from male and female donors. After a preincubation time of 15 min at 
37°C (A) 12-HETE and (B) 12-HHT formation was measured. Either basal 
activities were measured or cells were stimulated with A23187 (IO 30 µM), 
thrombin (TR 1 U/0.5 ml) or collagen (Coll 8 µg/0.5 ml) respectively. Reactions 
were stopped by addition of 2 ml methanol and samples were analyzed by RP-
HPLC. 12-HETE and 12-HHT formation in relation to progesterone plasma 
levels was compared. Data are given as ng/5 × 108 cells. 
 
This was confirmed by the analysis of platelets resuspended in male and 
female plasma with approximately the same progesterone levels. In fact, 
also under these conditions p12-LO activity resulted lower in female plasma 
(Fig. 10.2 A) and a strong variability for 12-HHT was observed (Fig. 10.2 
B). 
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Fig. 10.2 p12-LO and COX-1 activity in human platelets resuspended plasma 
from male and female donors with similar progesterone plasma levels 
Washed human platelets were resuspended in plasma from male and female 
donors (approx. 5 × 108 cells/0.5 ml). After a preincubation time of 15 min at 37°C 
(A) 12-HETE and (B) 12-HHT formation was measured. Either basal activities 
were measured or cells were stimulated with A23187 (IO 30 µM), thrombin (TR 1 
U/0.5 ml) or collagen (Coll 8 µg/0.5 ml) respectively. Reactions were stopped by 
addition of 2 ml methanol and samples were analyzed by RP-HPLC. (A) 12-HETE 
and (B) 12-HHT formation in relation to progesterone plasma levels was 
compared (male 4.2 nM, female 4.4 nM). Data are given as ng/5 × 108 cells 
 
The effective concentration of progesterone to influence p12-LO activity in 
isolated platelets was found to be between 0.3 and 1 µM (as previously 
shown, Fig. 8). Progesterone plasma levels in the female donors tested were 
below these concentrations (table 1). 
Nevertheless, when female platelets were incubated in male plasma 
supplemented with different concentrations of progesterone and were 
stimulated with thrombin 1 U/0.5 ml or collagen 8 µg/0.5 ml respectively, a 
slight inhibition of p12-LO activity could be observed (Fig. 10.4). 
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Fig. 10.4 12-HETE formation in platelets resuspended in male plasma 
supplemented with different progesterone concentrations Washed human 
platelets from female donors were resuspended in pooled male plasma (approx. 5 
× 108 /0.5 ml). After a preincubation time of 120 min at 37°C cells were stimulated 
with thrombin (1 U/0.5 ml) and collagen (8 µg/0.5 ml) respectively. As solvent 
control (ctr) 0.1% ethanol was used. Reactions were stopped by addition of 2 ml 
methanol and samples were analyzed by RP-HPLC. Data are given as mean ng/5 
× 108 cells + S.E. (n = 3-4) 
 
Taken together, progesterone had inhibitory effects on platelet 12-HETE 
formation, also when added to plasma. However, additional gender-related 
plasma factors might influence the behaviour of platelets, in particular in 
relation to the AA pathway, and therefore do not allow to establish a clear 
correlation between plasma (and the sex hormones therein) and 12-HETE 
production. 
3.2.4 p12-LO activity in plasma and PRP from pregnant donors 
In contrast to females and males with regular sex hormonal states, pregnant 
females show strongly elevated estrogen and progesterone plasma levels. To 
evaluate whether female hormones might influence p12-LO activity during 
pregnancy, the effect of plasma of pregnant donors on p12-LO activity in 
female platelets was analysed. However, no close correlation of p12-LO 
activity with progesterone plasma levels could be established (Fig. 10.3 A) 
when p12-LO activity of platelets resuspended in plasma from 5 different 
pregnant donors was compared. Plasma progesterone levels of individual 
donors are given in Table 2. 12-HETE formation was analysed in PRP from 
pregnant donors (Fig. 10.3 A) side by side with non-pregnant females and 
males (data not shown). 
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Pregnant donor Progesterone (nmol/l) 
Pregnant 1 275.3 
Pregnant 2 361.4 
Pregnant 3 437.1 
Pregnant 4 445.7 
Pregnant 5 1353.8 
Table 2 Progesterone levels of pregnant donors 
 
All data collected were pooled and mean p12-LO activities in male, female 
and pregnant plasma were determined (Fig. 10.3 B). No correlation between 
progesterone levels and p12-LO activity was found. Nevertheless, after 120 
min incubation a trend emerged in spontaneous 12-HETE formation (Fig. 
10.3 B) with lowest 12-HETE formation in pregnant and highest in male 
plasma. Thus, a connection to different progesterone plasma levels seems 
possible. 
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Fig. 10.3 p12-LO activity in human platelets resuspended in plasma from 
pregnant donors with different progesterone plasma levels Washed human 
platelets (5 × 108/ml) from female donors were resuspended in human citrate 
plasma from (A) pregnant and (B) male, female or pregnant donors. Cells were 
either incubated without stimulus for 15 or 120 min or were stimulated after a pre-
incubation time of 15 min with 30 µM A23187 (IO), 1 U/0.5 ml thrombin (TR) or 8 
µg/0.5 ml collagen (Coll) for 10 min. Reactions were terminated with 2 ml of 
methanol and analyzed by RP-HPLC. Pregnant plasma samples are n = 1 each 
donor, pooled data n = 6-9. Data in (A) are given as ng/5 × 108 cells, in (B) are 
given as mean ng/5 × 108 cells 
 
To collect more data on p12-LO activity in pregnant donors, also PRP 
isolated from male, female and pregnant donors was analyzed in regard to 
12-HETE and 12-HHT formation. Two independent experiments were 
performed. The respective plasmatic concentrations of sex hormones of all 
donors are reported in Table 3. 
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Gender Date Progesterone  Estradiol DHT 
Male 090910 3.2 nM 0.143 nM 13.1 nM 
Female 090910 4.1 nM 0.384 nM 1.9 nM 
Pregnant 090910 309.3 nM 2406.6 nM 2.2 nM 
Male 090708 2.3 nM 0.146 nM 20.8 nM 
Female 090708 1 nM 0.401 nM 1.8 nM 
Pregnant 090708 946.7 nM >367.0 nM 5.9 nM 
Table 3 Plasmatic concentrations of sex hormones in studied samples 
 
When the PRP from a pregnant donor with approx. 1 µM plasma 
progesterone was analysed, stimulated 12-HETE formation resulted lower 
than in PRP prepared from male or female (which did not significantly differ 
in 12-HETE formation, Fig. 11.1 A). However, when the experiment was 
performed with PRP from a pregnant donor with approx 0.3 µM 
progesterone levels, the effect observed was not as prominent, however, a 
lower p12-LO activity could still be found (Fig. 11.1 B). Interestingly, 
analysis of COX-1 activity in the PRP from both pregnant donors showed 
also reduced levels of 12-HHT (Fig. 11.1 C, Fig. 11.1 D). 
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Fig. 11.1 p12-LO and COX-1 activity in PRP isolated from male, female and 
pregnant donors PRP isolated from freshly drawn venous blood was 
incubated for either 15 or 120 minutes without stimulation at 37°C or stimulated 
for 10 min at 37 °C with thrombin (TR 1 U/0.5 ml) and collagen (Coll 8 µg/0.5 
ml), after a preincubation time of 15 minutes, CaCl2 (1 mM) was added at the 
beginning of the preincubation time. Progesterone levels of pregnant donors 
were determined at 1 µM for (A) and (C), 0.3 µM for (B) and (D). 12-LO activity 
measured is displayed in (A) and (B), values for COX-1 activity are given in (C) 
and (D). Reactions were stopped by addition of 2 ml methanol. Samples were 
extracted and analyzed via RP-HPLC analysis. Data are given as ng/ 5 × 108 
platelets (n = 2). Values have been normalized to represent 5 × 108 cells, as 
cell numbers strongly varied between donors. 
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To recreate progesterone concentrations in plasma as they are found during 
pregnancy, PRP from male donors (low natural progesterone levels, < 5 nM) 
were supplemented with different concentrations of progesterone. p12-LO 
product formation was lower in progesterone treated PRP than in the vehicle 
control samples (Fig. 11.2). The effect was clearly evident in collagen 
stimulated samples. Basal 12-HETE formation without stimulation was not 
determined in this set-up. 
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Fig.11.2 p12-LO activity in PRP isolated from male donors and supplemented 
with different progesterone concentrations PRP isolated from freshly drawn 
venous blood was supplemented with different concentrations of progesterone (0.1 
µM to 30 µM). PRP was incubated for 120 min. Then cells were stimulated with 
thrombin (TR 1 U/0.5 ml) or collagen (Coll 8 µg/0.5 ml). As control (ctr) 0.1% 
ethanol was used. Reactions were stopped by addition of 2 ml methanol and 
samples were analyzed by RP-HPLC. Data are given as mean ng/5 × 108 platelets 
+ S.E. (n = 4). Values have been calculated to represent 5 × 108 cells, as cell 
numbers varied strongly between donors. 
3.2.5 AA release in intact platelets from male and female 
donors treated with low hormone concentrations 
As previously shown, basal p12-LO activity was impaired by addition of 
low progesterone concentrations (1 µM, Fig. 8). Nevertheless, AA release in 
intact female platelets treated with the same concentrations of progesterone 
was not different compared to vehicle treated cells (Fig. 12), both in cells 
stimulated after a preincubation time of 30 min or left non-stimulated. 
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Fig. 12 Influence of low hormone concentrations on AA release in intact 
platelets Washed human platelets (108/ml in PG buffer) from female donors were 
incubated with the indicated hormones (progesterone Prog 1 and 3 µM, estradiol 
Est 0.1 µM, DHT 0.01 µM) for 30 min at 37°C. CaCl2 1 mM was added shortly 
before hormone supplementation. Samples were either stimulated with A23187 (IO 
2.5 µM) for 5 min or left untreated. As solvent control (ctr) 0.1% ethanol was used. 
Reactions were stopped with 2 ml methanol, released AA was derivatized and 
samples were analyzed by RP-HPLC. Data are given as mean % AA-release of 
standard (30 µg/ml margarinic acid) + S.E. (n = 3) 
3.2.6 AA release in intact platelets from female donors treated 
with high hormone concentrations 
High concentrations of progesterone, estradiol or DHT were tested for their 
ability to impair spontaneous AA release in intact platelets. Even at 
concentrations of 10 µM and long preincubation times of 30, 60 or 120 
minutes, no significant influence of either hormone could be detected on AA 
release in intact cells (Fig. 13.1). 
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Fig. 13.1 Influence of high hormone concentrations on AA release in intact 
platelets at different time points Washed human platelets (108/ml in PG buffer) 
from female donors were incubated with the indicated hormones (progesterone 
Prog, estradiol Est, DHT) in concentrations of 10 µM for 30, 60 or 120 min at 37°C. 
As solvent control (ctr) 0.1% ethanol was used. Reactions were stopped with 2 ml 
methanol, released AA was derivatized and samples were analyzed by RP-HPLC. 
Data are given as mean % AA-release of standard (30 µg/ml margarinic acid) + 
S.E. (n = 3) 
 
Also, no significant influence of sex hormones was detected when cells were 
stimulated with A23187 to release AA after a preincubation time of 30 
minutes with the different hormones (10 µM, Fig. 13.2). 
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Fig. 13.2 Influence of high hormone concentrations on AA release in intact 
platelets after A23187 stimulation Washed human platelets (108/ml in PG buffer) 
were incubated with the indicated hormones (progesterone Prog, estradiol Est, 
Dihydrotestosterone DHT) at a concentration of 10 µM for 30 min at 37°C. Cells 
were stimulated after 30 min with A23187 (2.5 µM for 5 min). As control (ctr) 0.1% 
ethanol was used. Reactions were stopped with 2 ml methanol, released AA was 
derivatized and samples were analyzed by RP-HPLC. Data are given as mean % 
AA release of standard (30 µg/ml margarinic acid) +S.E. (n = 3) 
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3.2.7 Influence of progesterone on cPLA2 activity in a cell free 
system 
To further exclude a connection of AA release to the effect of progesterone 
on p12-LO product formation, recombinant and partly purified cPLA2 was 
incubated with 10 µM progesterone. cPLA2 activity was measured by the 
ability to release AA (% rest activity) and was not inhibited by progesterone 
in a cell free assay (Fig. 14).  
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Fig. 14 Influence of progesterone on cPLA2 activity in a cell-free system 
Purified cPLA2 was incubated as described in the methods section. Progesterone 
(Prog, 10 µM), a defined cPLA2 inhibitor (pyrrolidine-1, 10 µM) or DMSO as solvent 
control (ctr) were added. Reactions were stopped by addition of 2 ml methanol, 
released AA was derivatized and samples were analyzed by RP-HPLC. Data is 
given as mean % rest activity + S.E. (n = 3). ***p< 0.001 vs. solvent control, 
ANOVA + Bonferroni post hoc tests. Measurements were performed together with 
Moritz Verhoff (University of Tübingen, Germany) 
3.2.8 Determination of p12-LO activity in platelet homogenates 
treated with sex hormones 
To evaluate whether the effect of progesterone observed in intact cells could 
be related to a direct inhibition of p12-LO activity, a cell free assay was 
performed. To this aim, platelets from female donors were first 
homogenized and then incubated (after homogenization) with progesterone 
(10 µM), estradiol (0.1 µM) or DHT (0.01 µM) (Fig. 15.1). AA (0.2 µM) 
was added as substrate. No direct inhibition of p12-LO in the homogenates 
was observed by any of the sex hormones, product amounts in hormone 
treated samples were the same as in vehicle treated cells. 
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Fig. 15.1 Effects of sex hormones in platelet homogenates incubated with sex 
hormones Washed human platelets were homogenized by sonification, cell rupture 
was checked under the microscope. Cell homogenates (1 ml corresponding to 108 
cells in PBS-EDTA) were pre-incubated on ice with hormones (Progesterone Prog 
10 µM, estradiol Est 0.1 µM, DHT 0.01 µM,) for 10 min, then incubated at 37°C for 
10 min with 0.2 µM AA as substrate. CaCl2 (1 mM) was added 50 s. before 
hormone addition. As solvent control (ctr), 0.1% ethanol was used. Reactions were 
stopped with 1 ml methanol and samples were analyzed by RP-HPLC. Data are 
given as mean ng/108 cells + S.E. (n = 3) 
 
These results indicate that progesterone (as well the other hormones tested) 
is not directly targeting p12-LO enzymatic activity. Interestingly, no 
significant effects of progesterone (and DHT or estradiol) were observed, 
also when cells were first incubated with hormones and then homogenates 
were prepared (Fig. 15.2). This suggests that an intact cellular environment 
is needed for the action of progesterone on p12-LO product formation, and 
then only the cellular p12-LO activity results influenced, as this effect is not 
persistent after homogenization. 
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Fig. 15.2 Effects of sex hormones on 12-LO activity in homogenates after 
preincubation of intact platelets Washed human platelets (108/ml in PG buffer) 
were incubated with the respective sex hormones (progesterone Prog 10 µM 
estradiol Est 0.1 µM, DHT D 0.01 µM,) for 30 min, resuspended in new buffer, and 
homogenized by sonification. Cell rupture was checked under the microscope. 
Homogenates were then incubated at 37°C for another 10 min with addition of 0.2 
µM AA as substrate. CaCl2 1 mM was added 50 s before hormone addition. As 
control (ctr) 0.1% ethanol was used. Reactions were stopped with 1 ml methanol 
and samples were analyzed by RP-HPLC. Data are given as mean ng/108 cells + 
S.E. (n = 3) 
3.2.9 Reversibility of the progesterone effect 
Progesterone was observed to have significant effects on cellular p12-LO 
activity. However, no difference between male and female platelets was 
observed (Fig. 1.1). To evaluate possible reasons for this discrepancy, the 
reversibility of the progesterone effect was evaluated. Platelets from female 
donors were incubated with progesterone (3 µM for 30 min). Progesterone 
was removed by a washing step with BSA 1 mg/ml in PG buffer and cells 
were then resuspended in PG buffer and incubated for another 30 min. 
Interestingly, platelets regained almost their full ability to form 12-HETE 
after progesterone had been removed from the sample (Fig. 16). Removal of 
progesterone was confirmed by evaluation of the HPLC-chromatogram 
(absorption at 280 nm) (data not shown). 
  68 
ctr Prog Prog wash
re
s
t a
c
tiv
ity
 
p1
2-
LO
 
(%
 
o
f c
o
n
tr
o
l)
0
20
40
60
80
100
120
*
 
Fig. 16 Reversibility of progesterone effect on p12-LO in intact human 
platelets Washed human platelets from female donors (108/ml in PG buffer) were 
incubated at 37°C for 30 min with ethanol as solvent control (ctr) or progesterone 3 
µM (Prog) and a washing step was performed as described in the methods section. 
Reactions were finally stopped with 1 ml methanol and samples were analyzed by 
RP-HPLC. Data are given as mean % rest activity of solvent control + S.E. (n = 3) * 
p 0.0245 vs. solvent control, ANOVA + Bonferroni post hoc tests 
3.2.10 Influence of progesterone on p12-LO subcellular 
localisation 
p12-LO activity is assumed to be connected to p12-LO translocation to the 
platelet membrane [95]. Inhibition of this translocation step could be 
responsible for a reduced 12-HETE formation in progesterone treated cells. 
However, progesterone (10 µM) was neither able to change subcellular 
localisation in non-stimulated cells nor to inhibit thrombin-induced 
translocation of p12-LO (30 min preincubation with progesterone, Fig. 17).  
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Fig. 17 Effect of sex hormones on translocation of p12-LO in intact cells (A as 
S100 and B as P 100) Female washed platelets (1 × 109/ml in PG buffer) were 
incubated for 30 min at 37°C with the indicated hormones (10 µM). CaCl2 (1 mM) 
was added 5 min before hormone addition. After 30 min samples were either 
stimulated with thrombin (TR 1 U/ml) or left non-stimulated. Reactions were 
stopped in N2 liq., cells were lysed by repeated freeze-thawing cycles (3 ×) and an 
ultracentrifugation step (1h, 4°C, 100,000 × g) was performed to separate (A) 
cytosolic (S 100) and (B) pelletable (P 100) fractions. S 100 and P 100 were mixed 
1:1 with SDS-loading buffer and separated via SDS-PAGE. p12-LO was 
determined by Western blot and Ettan Dige analysis. Data shown is representative 
for 3 individual experiments. 
 
Longer preincubation times with progesterone did not result in an inhibition 
of translocation (data not shown), despite very prominent effects on 12-
HETE formation. 
3.2.11 Platelet aggregation after progesterone treatment 
To evaluate whether the effect of progesterone might be related to a general 
change of platelet physiology, the aggregation of platelets was evaluated. 
Platelets were freshly isolated from citrate blood and incubated for different 
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times with progesterone (10 µM) or DMSO as solvent control. When cells 
were stimulated to aggregate with thrombin or collagen, no difference in 
aggregation was seen between platelets treated with progesterone and 
platelets treated with solvent, even when long preincubation times of 120 
minutes were applied (Fig. 18) 
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Fig. 18 Agonist induced platelet aggregation after treatment of platelets 
with progesterone Washed human platelets were resuspended in Tyrode´s 
buffer (2 × 108/ml) and preincubated with progesterone (Prog 10 µM) or DMSO 
(ctr 1 µl) for 120 min at RT. Platelet aggregation was recorded for 5 min using a 
turbidimetric light-transmittance device. CaCl2 (1 mM) was added right before 
the start of the measurement. Cells were stimulated with (A) 1 U/ml thrombin or 
(B) 1 µg/ml collagen, the aggregation response is given as percentage of the 
maximal light transmission Amax. Curves are representative for 3 independent 
determinations. 
3.2.12 Influence of progesterone on kinase activation status 
Sex hormones have been reported to influence signalling kinases via non-
genomic mechanisms, leading to rapid cellular effects. Since platelets are 
devoid of a nucleus and therefore lack genomic regulation, it was evaluated 
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whether the effect of progesterone on p12-LO might be mediated by 
activation or inhibition of kinase-mediated phosphorylation events. 
However, progesterone did not influence the basal phosphorylation state of 
the signalling kinases ERK, Akt, p38 or PKC or their main phosphorylation 
target MARCKS for PKC (Fig. 19). The result was the same whether male 
(data not shown) or female cells were used. An influence of agonist induced 
kinase activation was not examined since a progesterone effect on p12-LO 
activity was clearly observed in non-simulated and in stimulated platelets as 
well. 
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Fig. 19 Influence of progesterone on phosphorylation status of signalling 
kinases in human platelets Washed human platelets (108/0.1 ml PG buffer) were 
incubated for the indicated times with progesterone (10 µM) or ethanol (0.1%) as 
solvent control, respectively. CaCl2 (1 mM) was added on ice before aliquoting the 
cells. As positive control cells were stimulated with thrombin (1 U/ml), collagen (12 
µg/ml) or PMA (100 nM) for 7 min at 37°C. Samples were stopped after the 
indicated times by addition of SDS-loading buffer 1:1 and were separated by SDS-
PAGE. Activation of Akt, PKC (via MARCKS), ERK and p38 was determined by 
Western blot using specific antibodies. Data shown are representative for 3 
individual experiments.  
3.2.13 Influence of hormone addition on [Ca2+]i in intact 
platelets  
It has previously been reported that progesterone metabolites are able to 
influence [Ca2+]i in platelets [180]. Thus, the effect of sex hormones on 
[Ca2+]i levels was evaluated. However, neither progesterone nor estradiol or 
DHT induced [Ca2+]i influx in platelets, when directly added to the cells 
(Fig. 20.1).  
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Fig. 20.1 Effect of direct sex hormone addition on [Ca2+]i influx in intact 
platelets To Fura-2 loaded female cells (108/ml PG buffer) CaCl2 (1 mM) was 
added 60 s prior start of measurement of [Ca2+]i. Progesterone (Prog), estradiol 
(Est) and DHT were added at a concentration of 10 µM after 30 s. Cells were left 
untreated and [Ca2+]i was measured for 280 s. As solvent control (ctr) 0.1% DMSO 
was used. Data shown is representative of 3 individual experiments. 
 
Also, hormone addition immediately followed by stimulation with thrombin 
or collagen did not result in a significant change of agonist-mediated [Ca2+]i 
mobilisation (Fig. 20.2). 
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Fig. 20.2 Effect of direct sex hormone addition on agonist induced [Ca2+]i 
influx in intact platelets To Fura-2 loaded female cells (108/ml in PG buffer) CaCl2 
(1 mM) was added 60 s prior start of measurement of [Ca2+]i, Hormones 
progesterone (Prog), estradiol (Est) and DHT were added at a concentration of 10 
µM 30 s. Cells were stimulated with (A) thrombin 1 U/ml or (B) collagen 12 µg/ml 
after 110 s and [Ca2+]i was measured for 280 s. As solvent control (ctr) 0.1% DMSO 
was used. Data shown is representative of 3 individual experiments. 
 
Pre-incubation of platelets with hormones (10 µM) for 60 minutes did not 
change [Ca2+]i levels after stimulation of cells with thrombin or collagen 
(Fig. 20.3). Longer pre-incubation times did not give any effect either (data 
not shown). 
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Fig. 20.3 Effect of sex hormones on agonist induced [Ca2+]i elevation in intact 
platelets after incubation for 60 minutes To Fura-2 loaded female cells (108/ml 
PG buffer) progesterone (Prog), estradiol (Est) and DHT were added at a 
concentration of 10 µM and samples were incubated for 60 min at 37°C under light 
protection. CaCl2 1 mM was added 60 s prior to start of measurement. Cells were 
stimulated with (A) thrombin (1 U/ml) or (B) collagen (12 µg/ml) 30 s after start of 
measurement of [Ca2+]i. As solvent control (ctr) 0.1% DMSO was used. Data shown 
is representative of 3 individual experiments. 
3.2.14 Influence of protein kinase A (PKA) activators and 
inhibitors on p12-LO activity and on the effect of 
progesterone 
The most prominent and well-recognized inhibitory pathway for platelet 
functions is represented by protein kinase A [181]. To investigate whether 
the progesterone effect involves PKA activation, female platelets were 
treated with the PKA inhibitor H89 (10 µM) [182] and progesterone (3 µM) 
simultaneously. H89 treatment reversed progesterone-induced inhibition of 
p12-LO slightly although no full recovery of p12-LO activity was achieved 
(Fig. 21). Also, the PKA activator PGE2 inhibited 12-HETE formation in 
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platelets at a concentration of 5 µM but its effect could not be reversed by 
co-incubation with H89. The PKA inhibitor itself did not show any effects 
on p12-LO. 
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Fig. 21 Influence of PKA inhibitors and activators on p12-LO activity Washed 
human platelets (108/ml PG buffer) from male and female donors were incubated 
for 60 min at 37°C with vehicle controls, progesterone (Prog 3 µM), H 89 (10 µM), 
PGE2 (5 µM) and combinations, as indicated. CaCl2 (1 mM) was added 50 s before 
addition of the substances. As control (ctr) ethanol and DMSO combined in a 
concentration of 0.1% each were used. After 60 min reactions were stopped by 
addition of 1 ml methanol and samples were analyzed by RP-HPLC. Data are given 
as % rest activity of solvent control + S.E. (n = 3) 
3.2.15 Influence of the cAMP analogue 8-bromo-cAMP on p12-
LO activity 
To confirm a possible role of PKA as mediator of the progesterone effect on 
p12-LO the capacity of cAMP analogue 8-bromo-cAMP on p12-LO activity 
was tested in intact cells. When 8-bromo-cAMP (1 mM) was added to intact 
cells and incubated for 60 min, a very slight inhibition of p12-LO activity 
could be measured in comparison to the control sample. 
 
  76 
w/o 8-bromo
re
st
 
a
ct
iv
ity
 
p1
2-
LO
 
(%
 
o
f c
o
n
tr
o
l)
0
20
40
60
80
100
120
male
female
 
Fig. 22 Influence of cAMP analogue 8-bromo-cAMP on p12-LO product 
formation Washed human platelets (108/ml in PG buffer) were incubated for 60 
min. at 37°C with 8-bromo-cAMP (1 mM). CaCl2 (1 mM) was added 50 s prior 8-
bromo-cAMP. Reactions were stopped by addition of 1 ml methanol and samples 
were analyzed by RP-HPLC. Data are given as % rest activity of control (w/o) + 
S.E. (n = 3)  
3.2.16 Occurrence of classical progesterone receptors in 
platelets 
Next, the occurrence of the classical progesterone receptor was evaluated in 
platelets. Platelets of both genders do not express the classical hormone 
receptor for progesterone. Western Blot signals for the corresponding 
proteins were not found (Fig. 23.1). As positive control PC-3 cell lysates 
were used (according to the antibody manual supplied by the manufacturer). 
However, also signals of the control cells were very weak. 
PR B 116 kDa
PR A 81 kDa
Platelets
Male        Female
PC-3
 
Fig. 23.1 Occurrence of classical progesterone receptors PR-A and PR-B in 
human platelets Washed platelets from male and female donors (1 × 109/ml in PG 
buffer) were lysed by addition of SDS-loading buffer 1:1 to the cells. Proteins were 
separated by SDS-PAGE and analyzed by Western blot. As positive controls PC-3 
cells were used in a concentration of 1 × 107/ml. Data shown is representative for n 
= 3 experiments performed separately. 
 
Next, it was evaluated whether mifepristone, a progesterone receptor 
antagonist with a 5-fold higher affinity to the classical progesterone receptor 
than progesterone itself, could block the effect of progesterone. 
3 Results  77 
Interestingly, when female platelets were co-incubated with mifepristone (3 
µM) and progesterone (3 µM), mifepristone was not able to abolish the 
progesterone effect on p12-LO product formation (Fig. 23.2). The results 
were the same if male cells were used (data not shown). 
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Fig. 23.2 Effect of progesterone receptor antagonist mifepristone on 
progesterone inhibition of p12-LO product formation in intact human 
platelets Washed female platelets (108/ml PG buffer) were incubated with 
progesterone (Prog 3 µM), mifepristone (Mife 3 µM) and a combination of both for 
120 min. CaCl2 (1 mM) was added 50 s before hormone addition. As solvent 
control (ctr) ethanol and DMSO in a concentration of each 0.1% were used in 
combination. Reactions were stopped by addition of 1 ml methanol, samples were 
analyzed by RP-HPLC: Data are given as mean ng/108 cells + S.E. (n = 3). 
 
A progesterone derivative [183], cyproterone with a slight progestinic 
activity also inhibited basal 12-HETE formation, although in a slightly 
weaker manner (Fig. 23.3). The results were the same if male cells were 
used (data not shown). 
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Fig. 23.3 Effect of cyproterone on p12-LO product formation in intact human 
platelets Washed female platelets (108/ ml in PG buffer) were incubated with 
progesterone (3 µM) and cyproterone (3 µM) for 120 min, respectively. CaCl2 (1 
mM) was added 50 s before hormone addition. As solvent control (ctr) 0.1% 
ethanol was used. Reactions were stopped by addition of 1 ml methanol, samples 
were analyzed by RP-HPLC: Data are given as mean ng/108 cells + S.E. (n = 3) 
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3.3. p12-LO inhibitor cinnamyl-3,4 dihydroxy-α-
cyanocinnamate (CDC) and its pharmacological 
profile in platelets 
Cinnamyl-3,4 dihydroxy-α-cyanocinnamate (CDC) was characterized as 
selective p12-LO inhibitor [147]. CDC was therefore used in this work as a 
control inhibitor in p12-LO activity assays and has also frequently been used 
by different work groups to define p12-LO involvement in various 
pathophysiological conditions [112, 154]. However, CDC not only inhibited 
p12-LO activity in the control samples but surprisingly also inhibited COX-
1 with comparable potency. To further characterize its pharmacological 
profile, CDC was more closely investigated. 
3.3.1. Influence of CDC on p12-LO and COX-1 in intact 
platelets 
CDC was added to freshly isolated washed platelets. CDC inhibited p12-LO 
activity as well as COX-1 activity in intact cells (Fig. 24). Though CDC had 
been termed a selective p12-LO inhibitor [147], its capacity to inhibit COX-
1 activity was even more prominent in some cases than its inhibition of 12-
HETE formation in intact cells. In particular when cells were stimulated 
with AA (3 µM), p12-LO activity was not inhibited, while COX-1 product 
formation was blocked with an IC50 of 3 µM CDC (Fig. 24 D).  
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Fig. 24 Effect of CDC on p12-LO and COX-1 activity in washed human 
platelets stimulated with different platelet agonists Washed human platelets 
(108/ml PG buffer) were pre-incubated with CDC in the indicated concentrations for 
20 min at 37°C. Platelets were then stimulated with (A) 1 U/ml thrombin, (B) 8 
µg/ml collagen, (C) 2.5 µM A23187, (D) 3 µM AA for 10 min. CaCl2 (1 mM) was 
added 60 s before CDC. Reactions were terminated by addition of 1 ml methanol 
and samples were analyzed by RP-HPLC. As solvent control (ctr) 0.2% DMSO was 
used. Data are given as % remaining activity of solvent control for p12-LO and 
COX-1 respectively, + S.E. (n = 3). IC50 values for CDC were determined to be 
between 0.3 and 10 µM for both enzymes depending on assay design except for 
AA stimulation, where the IC50 for p12-LO was > 30 µM.  
 
3.3.2. Inhibition of p12-LO and COX-1 by CDC in platelet 
homogenates 
To distinguish between a direct inhibition of COX-1 and p12-LO and effects 
only mediated in the intact cell, platelet homogenates were treated with 
different concentrations of CDC. p12-LO was potently inhibited in platelet 
homogenates, CDC could be confirmed as a direct p12-LO inhibitor. But 
also COX-1 was potently inhibited as observed in intact platelets, indicating 
that CDC might also be a direct inhibitor of COX-1 (Fig. 24). 
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Fig. 25 Effect of CDC on p12-LO and COX-1 activity in platelet homogenates 
Washed platelets were homogenized by sonification, cell rupture was checked 
under the microscope. Cell homogenates (1 ml corresponding to 108 cells in PBS-
EDTA) were pre-incubated with CDC at the indicated concentrations for 20 min on 
ice, then for another 10 min at 37°C with AA (3 µM) as substrate. CaCl2 was added 
60 s before CDC on ice. As solvent control (ctr) 0.2% DMSO was used. Reactions 
were terminated with 1 ml methanol and samples were analyzed by RP-HPLC. 
Data are given as mean % remaining activity of solvent control + S.E. (n = 3) IC50 
for COX-1 and p12-LO inhibition was determined as 10 µM. 
3.3.3. Influence of CDC on COX-1/2 and cPLA2 in a cell free 
system 
More detailed studies of CDC effects on COX-1/2 in a cell free system 
revealed that CDC did in fact not inhibit purified COX-1/2 enzymes at all 
and thus a direct inhibitory mechanism of COX enzymes can be excluded 
(Fig. 26.1). 
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Fig. 26.1 Effect of CDC on COX-1/2 activity in a cell free assay Purified COX-1 
and COX-2 enzymes were pre-incubated with CDC in the indicated concentrations 
at 4°C for 5 min. Samples were then pre-warmed for 60 s at 37°C, AA (5 µM) was 
added and samples were incubated for 5 more min. Reactions were stopped by 
addition of 1 ml methanol, COX-1/2 product 12-HHT was extracted and analyzed 
by RP-HPLC. As control inhibitors (inh) indomethacin (10 µM) for COX-1 and 
celecoxib (10 nM) for COX-2 were used, solvent control (ctr) was 0.1% DMSO. 
Data are given as mean % rest activity of solvent control + S.E. (n = 3)  
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CDC was not able to impair cPLA2 activity in a cell-free assay (Fig. 26.2), a 
direct inhibition of cPLA2 by CDC could be excluded. The strong inhibition 
of COX-1 activity in intact platelets and platelet homogenates could thus not 
completely be attributed to a direct inhibition and lowered AA-release but 
seemed to target more complex regulatory mechanisms. 
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Fig. 26.2 Effect of CDC on cPLA2 activity in a cell free system Purified cPLA2 
was incubated for 60 min with CDC in the indicated concentrations as described in 
the methods section. Reactions were stopped with 1 ml methanol, released AA was 
extracted and derivatized with p-anisidinium chloride for 60 min. Samples were 
then analyzed by RP-HPLC. As controls EDTA and a cPLA2 inhibitor (pyrrolidine-1 
10 µM) were used, solvent control (ctr) was 0.1% DMSO. Data are given as % rest 
activity of DMSO control 
3.3.4. Influence of CDC on AA release in intact platelets 
AA release was also measured in intact cells using tritium-labelled AA to 
determine the effect of CDC to decrease AA release in a cellular 
environment (Fig. 27). Thrombin- as well as A23187 -induced AA release 
were suppressed by CDC with IC50 determined at 3 µM for A23187 and at 
0.3 µM for thrombin.  
3 Results  83 
CDC [µM]
w/o ctr 0.3 1 3 10 30 cPLA2- I
AA
-relea
se
 (x
-fold
 of
 w
/o
 co
ntrol)
0
1
2
3
4
5
6
7
IO
TR
 
Fig. 27 Effect of CDC on AA release in intact platelets stimulated with 
thrombin and A23187 Freshly isolated PRP was labelled with [3H] AA (1 µCi/ml) 
for 120 min at 37°C. Cells were washed to remove non-incorporated AA and were 
treated with CDC (108/ml) at the indicated concentrations. To stimulate AA-release 
thrombin (TR 1 U/ml) or A23187 (IO 2.5 µM) were added, as solvent control (ctr) 
0.1% DMSO was used. Total amounts of radioactive AA and AA-metabolites were 
measured via scintillation counter. Data are given as % rest activity of DMSO 
control + S.E. (n = 3).  
3.3.5. Influence of CDC on [Ca2+]i mobilisation in platelets 
Enzyme activities in platelets are closely regulated by the amounts of [Ca2+]i 
[11]. Impairing [Ca2+]i mobilisation could add to the inhibitory effect of 
CDC on COX-1 and p12-LO activity in platelets. Thus the influence of CDC 
on agonist-induced change in [Ca2+]i levels was determined. CDC was able 
to suppress [Ca2+]i mobilisation in comparison to solvent control when cells 
were stimulated by thrombin (Fig. 28.1). Thrombin-induced [Ca2+]i 
mobilisation was reduced markedly by 10 µM CDC and completely 
abolished by 30 µM CDC (Fig. 28.1).  
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Fig. 28.1 Effect of CDC on thrombin-induced [Ca2+]i mobilisation in intact 
human platelets To Fura-2 loaded female cells (108/ml in PG buffer) CDC in the 
indicated concentrations or DMSO as vehicle control were added and samples 
were incubated for 20 incubation at 37°C under light protection. CaCl2 (1 mM) was 
added 60 s prior to start of measurement. Cells were stimulated with thrombin 1 
U/ml 30 s after start of measurement of [Ca2+]i. As solvent control (ctr) 0.1% 
DMSO was used. Data shown is representative of 3 individual experiments.  
 
When collagen was used as agonist to induce [Ca2+]i mobilisation a strong 
inhibitory effect by CDC could already be observed at 0.3 µM and [Ca2+]i 
elevation was completely blocked at a concentration of 10 µM CDC (Fig. 
28.2). 
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Fig. 28.2 Effect of CDC on collagen-induced [Ca2+]i mobilisation in intact 
human platelets To Fura-2 loaded female cells (108/ml in PG buffer) CDC at the 
indicated concentrations or DMSO as vehicle control were added and samples 
were incubated for 20 incubation at 37°C under light protection. CaCl2 (1 mM) was 
added 60 s prior to start of measurement. Cells were stimulated with collagen (12 
µg/ml) 30 s after start of measurement of [Ca2+]i. As solvent control (ctr) 0.1% 
DMSO was used. Data shown are representative of 3 individual experiments.  
3 Results  85 
3.3.6 Influence of CDC on ROS formation in platelets 
CDC as structural derivative of caffeic acid [147] could possibly possess 
anti-oxidative characteristics. Its ability to prevent formation of reactive 
oxygen species (ROS) was determined. When thrombin (0.5 U/ml) or 
collagen (8 µg/ml) were used to stimulate cells, almost no ROS formation 
could be measured in platelets treated with 10 or 30 µM CDC in comparison 
to solvent control, a marked decrease of ROS formation was already 
observed at 0.3 µM CDC (Fig. 29). 
 
CDC [µM]
ctr 0.1 0.3 1 3 
RO
S 
fo
rm
at
io
n
 
(%
 
o
f s
o
lv
en
t c
o
n
tr
o
l)
0
20
40
60
80
100
120
TR
Coll
 
Fig. 29 Effect of CDC on agonist induced ROS formation in intact human 
platelets Washed human platelets were incubated with CDC at the indicated 
concentrations for 20 min at 37°C. Measurement was started 5 min after addition of 
fluorescent dye. ROS formation was induced by stimulation of cells with thrombin 
(TR 1 U/ml) and collagen (Coll 12 µg/ml). 0.2% DMSO was used as solvent control 
(ctr). Data are given as % ROS formation of solvent control and are representative 
for 3 experiments performed separately. EC50 = 0.1 µM. 
3.3.7 Inhibition of p12-LO and COX-1 by CDC in whole blood 
and PRP 
To characterize the efficiency of CDC in a more physiological system, 
whole blood assays were performed. IC50 values were determined at about 
30 µM for p12-LO and > 30 µM for COX-1 (Fig. 30.1).  
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Fig. 30.1 Effect of CDC on p12-LO and COX-1 product formation in whole 
blood Freshly drawn venous citrate blood was incubated with CDC at the indicated 
concentrations for 20 min at 37°C. After 20 min p12-LO and COX-1 activity was 
induced by addition of 30 µM A23187. Reactions were stopped after 10 min on ice, 
samples were centrifuged (600 × g, 10 min, 4°C) and plasma supernatants were 
collected. Samples were prepared for HPLC as described and p12-LO and COX-1 
product formation was analyzed. As solvent control (ctr) 0.1% DMSO was used. 
Data are given as mean % rest activity of solvent control + S.E. (n = 3-4). IC50 were 
determined at 3 µM for p12-LO and 30 µM for COX-1. 
 
However, when CDC was added to PRP prepared from freshly drawn citrate 
blood, the inhibitory potential of CDC was less prominent, although a 
similar result as in whole blood could be seen. CDC inhibited both COX-1 
and p12-LO with an IC50 > 30 µM (Fig. 30.2).  
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Fig. 30.2 Effect of CDC on p12-LO and COX-1 product formation in PRP PRP 
freshly prepared from human venous citrated blood was incubated with CDC at the 
indicated concentrations for 20 min at 37°C. After 20 min. p12-LO and COX-1 
activity was induced by addition of 100 µM AA. CaCl2 (2 mM) was added 50 s prior 
CDC. Reactions were stopped after 10 min by addition of 2 ml methanol and 
samples were analyzed by RP- HPLC. Data are given as mean % rest activity of 
solvent control + S.E. (n = 3). IC50 for p12-LO and COX-1 were determined at > 30 
µM. 
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3.3.8 Influence of CDC on platelet aggregation induced with 
different stimuli 
CDC was able to block COX-1 activity as well as [Ca2+]i elevation in 
thrombin and collagen stimulated cells. As both events are closely connected 
to platelet aggregation the effect of CDC on platelet aggregation was 
investigated. Freshly prepared washed human platelets were treated with 
different concentrations of CDC. At concentrations of 10 and 30 µM an 
inhibition of collagen-induced aggregation was observed (Fig. 31.1). 
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Fig. 31.1 Effect of CDC on collagen induced platelet aggregation of platelets 
Washed human platelets were resuspended in Tyrode´s buffer (2 × 108/ml). 
Platelet aggregation was recorded for 5 min using a turbidimetric light-
transmittance device. CaCl2 1 mM was added right before the start of the 
measurement. Cells were pre-incubated for 20 min with CDC in the indicated 
concentrations. As control indomethacin (indo 20 µM) was used as inhibitor of 
platelet aggregation. Cells were stimulated with 0.5 µg/ml collagen, the aggregation 
response is given as percentage of the maximal light transmission Amax. Curves are 
representative for 3 independent determinations. 
 
When cells were stimulated with AA (200 µM), thromboxane analogue U 
46619 (1 µM) or thrombin (1U/ml) to induce aggregation CDC did not 
prevent aggregation even at concentrations of 30 µM (Fig. 31.2 A-C). 
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Fig. 31.2 Effect of CDC on AA-, U46619- and thrombin-induced platelet 
aggregation Washed human platelets were resuspended in Tyrode´s buffer (2 × 
108/ml). Platelet aggregation was recorded for 5 min using a turbidimetric light-
transmittance device. CaCl2 (1 mM) was added right before the start of the 
measurement. Platelets were preincubated for 20 min with CDC (10 and 30 µM). 
As controls indomethacin 10 µM was used as inhibitor of platelet aggregation and 
0.1% DMSO as solvent control. Platelets were stimulated with (A) AA (200 µM), (B) 
U46619 (1 µM) or (C) thrombin (1 U/ml). The aggregation response is given as 
percentage of the maximal light transmission Amax. Curves are representative for 3 
independent determinations. 
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Also, TXB2-levels after stimulation of intact cells and in homogenates were 
determined. TXB2 is the stable metabolite of TXA2 which is closely 
connected to platelet aggregation [20]. TXB2 formation was significantly 
reduced at CDC concentrations of 3 to 10 µM as well in intact cells 
stimulated with 1 U/ml thrombin or 8 µg/ml collagen (Fig. 31.3). 
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Fig. 31.3 CDC Inhibition of TXB2 formation in washed human platelets Washed 
human platelets (108/ml) were pre-incubated with CDC in the indicated 
concentrations for 20 min at 37°C. After 20 min cells were stimulated with (A) 
thrombin (1 U/ml) and collagen (8 µg/ml) and (B) AA (3 µM) and A23187 (2.5 µM) 
respectively. CaCl2 (1 mM) was added 60 s before CDC. As solvent control 0.2% 
DMSO was used. Reactions were stopped on ice and TXB2 formation was 
determined following the manufacturer’s manual of the used ELISA kit. Data (mean 
+ S.E.; n = 3) are given as percentage of solvent control (100%). 
 
Altogether, CDC proved to be much more than just a p12-LO inhibitor that 
can easily be used as a pharmacological tool for analysis of the p12-LO 
pathway. In fact, when using CDC many regulatory pathways could possibly 
be affected and contribute to the observed effect independent of p12-LO. 
  90 
3.4  Effects of MK-886 on p12-LO in platelets 
MK-886 is a well known and frequently used FLAP and mPGES-1 inhibitor 
and was also described as a COX-1 inhibitor [157]. As the p12-LO and the 
5-LO pathway are structurally related [184] it was reasonable to investigate 
whether MK-886 may affect p12-LO in intact platelets. COX-1 activity was 
analysed for control, as platelets also express COX-1 [86]. 
3.4.1 Influence of MK-886 on p12-LO and COX-1 activity in 
washed platelets 
When intact platelets were treated with different concentrations of MK-886, 
an increase in 12-LO product formation could be seen at a concentration of 
10 µM MK-886 in comparison to the solvent control without addition of any 
stimulus after a pre-incubation of 20 min. This effect vanished when the 
cells were subsequently stimulated with various agents (Fig. 32.1). 
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Fig. 32.1 p12-LO activity in intact platelets treated with MK-886 Washed human 
platelets from female donors (108/ml in PG buffer) were incubated with MK-886 (10 
µM) for 20 min at 37°C. Cells were either stimulated with collagen (8 µg/ml), 
thrombin (TR 1 U/ml), AA (AA 3 µM) or A23187 (IO 3 µM) or ethanol for another 10 
min. CaCl2 (1 mM) was added 50 s before MK-886. Reactions were stopped by 
addition of 1 ml methanol, and samples were analyzed for 12-HETE by RP-HPLC. 
Data are given as mean ng/108 cells + S.E. (n = 3). 
 
For COX-1 product formation a similar stimulatory effect could be 
observed, although the increase in product formation was not as strong as for 
p12-LO (Fig. 32.2). However, in stimulated samples COX-1 product 
formation decreased with increasing MK-886 concentration, corresponding 
to MK-886 characteristics as a COX-1 inhibitor [157]. 
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Fig.32.2 COX-1 activity in intact platelets treated with MK-886 Washed human 
platelets from female donors (108/ ml in PG buffer) were incubated with MK-886 (10 
µM) for 20 min at 37°C. Cells were either stimulated with collagen (8 µg/ml), 
thrombin (TR 1 U/ml), AA (AA 3 µM) or A23187 (IO 3 µM) or ethanol for another 10 
min. CaCl2 (1 mM) was added 50 s before MK-886. Reactions were stopped by 
addition of 1 ml methanol and samples were analyzed by RP-HPLC. Data are given 
as mean ng/108 cells + S.E. (n = 3). 12-HHT as stable COX-1 metabolite was used 
for determination of COX-1 activity. 
 
The efficiency of MK-886 was assessed by performing concentration-
response assays. A concentration of 10 µM gave maximal p12-LO product 
formation and led to a 40-fold increase in comparison to the DMSO control. 
A comparable effect could be observed for COX-1 product formation as 
well, where an increase of about 10-fold was observed (Fig. 32.3).  
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Fig.32.3 Increase of p12-LO and COX-1 product formation in MK-886 treated 
human platelets without stimulation Washed human platelets from female 
donors (108/ml in PG buffer) were incubated with the indicated concentrations of 
MK-886 for 20 min at 37°C. CaCl2 (1 mM) was added 50 s before MK-886. 
Reactions were stopped by addition of 1 ml methanol and samples were analyzed 
by RP-HPLC. (A) p12-LO product formation measured as 12-HETE. (B) COX-1 
product formation measured as 12-HHT. Data are given as x-fold increase of 
product in comparison to solvent control + S.E. for both p12-LO and COX-1 (n = 3) 
*p 0.05 ANOVA + Bonferroni post hoc test 
3.4.2. Effect of MK-886 on p12-LO and COX-1 in AA 
supplemented platelets and platelet homogenates 
Different mechanisms may exist by which MK-886 could exert its effect on 
p12-LO and COX-1. MK-886 could directly stimulate both enzymes but 
also may increase the availability of substrate AA for both enzymes. When 
cells were supplemented with 10 µM AA, no stimulating effect of MK-886 
on the activity of both enzymes could be observed. p12-LO product 
formation remained approximately the same for all MK-886 concentrations, 
whereas COX-1 activity decreased significantly with rising MK-886 
concentrations (Fig. 33.1), as expected [157]. 
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Fig. 33.1 Effect of MK-886 on p12-LO and COX-1 activity in intact human 
platelets supplemented with arachidonic acid Washed human platelets (108/ ml 
in PG buffer) were incubated with the indicated concentrations of MK-886 for 20 
min at 37°C. CaCl2 (1 mM) was added 50 s before MK-886. Cells were then 
stimulated for 10 min with arachidonic acid (10 µM). Reactions were stopped with 1 
ml methanol and samples were analyzed by RP-HPLC. Data are given as % rest 
activity of solvent control + S.E. (n = 3) and were determined using 12-HETE as 
indicator for p12-LO activity and 12-HHT for COX-1 activity. 
 
In platelet homogenates, MK-886 showed neither a stimulating effect on 
p12-LO nor on COX-1 activity. No increase in product formation for p12-
LO or COX-1 could be observed at any MK-886 concentration in 
homogenates supplemented with exogenous arachidonic acid (Fig. 33.2). 
Instead, for COX-1 product formation, a slight decrease in 12-HHT amounts 
could be observed for rising MK-886 concentrations (Fig. 33.2 B). 
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Fig. 33.2 Effect of MK-886 on p12 LO and COX-1 activity in platelet 
homogenates Washed human platelets from female donors were homogenized by 
sonification. Cell rupture was checked under the microscope. Homogenates (1 ml 
corresponding to 108 cells in PBS-EDTA) were incubated with MK-886 in the 
indicated concentrations for 10 min on ice. Homogenates were then supplemented 
with AA (10 µM) and incubated for another 10 min at 37°C. CaCl2 (1 mM) was 
added 50 s before MK-886 on ice. Reactions were stopped with 1 ml methanol, and 
samples were analyzed by RP-HPLC. (A) 12-HETE formation and (B) 12-HHT 
formation were measured as means to determine p12-LO and COX-1 activity 
respectively. Data are given as mean ng/108 cells + S.E. (n = 3). 
 
In homogenates, where no exogenous arachidonic acid was added, also no 
activating effect of MK-886 on p12-LO and COX-1 activities could be 
observed (data not shown).  
3.4.3. Influence of MK-886 on AA release in intact platelets and 
on cPLA2 activity in a cell free system 
Treatment of intact platelets with varying concentrations of MK-886 led to 
an increase in AA release with a maximum at 10 µM MK-886. The AA 
liberation was approximately 4-fold enhanced in comparison to DMSO 
control after an incubation time of 20 min (Fig. 34.1). 
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Fig. 34.1 AA release in intact human platelets in response to MK-886.Washed 
human platelets (108/ml in PG buffer) were incubated with indicated concentrations 
of MK-886 at 37°C for 20. As control a cPLA2 inhibitor (10 µM) was used. CaCl2 (1 
mM) was added 50 s before MK-886. Reactions were stopped with 2 ml methanol, 
released AA was derivatized, and samples were analyzed by RP-HPLC. Data are 
given as mean x-fold increase of AA in comparison to solvent control +S.E. (n = 3) 
 
To investigate whether MK-886 was activating cPLA2 directly, different 
concentrations of MK-886 were tested in a cell free cPLA2 assay. 
Recombinantly expressed purified cPLA2 was incubated for 60 min with 
different concentrations of MK-886 in a solution of AA-containing vesicles. 
Amounts of released AA were determined by HPLC after a derivatisation 
step. No direct activation of cPLA2 could be observed (Fig. 34.2). 
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Fig. 34.2 Effect of MK-886 on the activity of cPLA2 in a cell free system 
Purified cPLA2 was incubated for 60 min with MK-886 in the indicated 
concentrations and the activity was determined as described in the methods 
section. The cPLA2 inhibitor (pyrrolidine-1 10 µM) or DMSO as solvent control (ctr) 
were added. Reactions were stopped by addition of 2 ml methanol, released AA 
was derivatized and samples were analyzed by RP-HPLC. Data is given as mean 
% rest activity + S.E. (n = 3). Measurements were performed by M. Verhoff 
(University of Tübingen, Germany). 
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3.4.4. MK-886 induced [Ca2+]i mobilisation in platelets and PMNL  
Recently it has been found that MK-886 is also able to induce [Ca2+]i influx 
in PC-3 cells (prostate carcinoma cell line) [168]. As cPLA2 is strongly 
influenced by [Ca2+]i levels in the cell and in the surrounding buffer system, 
[Ca2+]i mobilisation in response to MK-886 was also analyzed in platelets. 
At a concentration of 10 µM, MK-886 caused a strong increase in [Ca2+]i 
levels (Fig. 35.1) also in platelets.  
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Fig. 35.1 Effect of MK-886 on intracellular [Ca2+]i levels in intact human 
platelets To Fura-2 loaded female platelets (108/ml in PG buffer) CaCl2 (1 mM) 
was added 60 s. prior start of measurement of [Ca2+]i. MK-886 in the indicated 
concentrations or DMSO 1 µl as vehicle control were added after 30 s. Cells were 
left non-stimulated and [Ca2+]i. was measured for 180 s. Data are given as 
[Ca2+]i.in nM/108 cells and are representative of 3 individual experiments. 
 
An even stronger [Ca2+]i elevation equivalent to agonist stimulation was 
found when platelets were treated with 30 µM MK-886 (Fig. 35.1 B). To 
find out whether this was a platelet specific effect, also PMNL were treated 
with MK-886 at different concentrations, and intracellular [Ca2+]i elevation 
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was measured. At a concentration of 30 µM MK-886, a slight increase could 
be detected shortly after MK-886 addition. This effect was more prominent 
when a concentration of 50 µM was added to the PMNL (Fig. 35.2). 
Another FLAP inhibitor, licofelone [185] was tested in the same set-up at a 
concentration of 50 µM. Also licofelone induced an elevation of [Ca2+]i in 
PMNL (data not shown). 
(sec)
0 10 20 30 40 50 60 70 80 90 100 110 120 130
Ca
2+
 
[i]
 
n
M
-20
-10
0
10
20
30
40
DMSO
MK 886 30 µM
MK 886 50 µM
 
Fig. 35.2 Effect of MK-886 on [Ca2+]i levels in intact PMNL To Fura-2 loaded 
female PMNL (106/ml in PG buffer), CaCl2 1 mM was added 60 s prior start of 
measurement of [Ca2+]i. MK-886 in the indicated concentrations or DMSO 1 µl as 
vehicle control were added after 30 s. Cells were left non-stimulated, and [Ca2+]i 
was measured for 180 s. Data shown is representative of 3 individual experiments. 
 
In conclusion as many studies especially concerning studies investigating 
the role of the 5-LO pathway in apoptosis or mechanisms of cancer 
development use MK-886 as a pharmacological tool at concentrations of 10 
to 50 µM, an effect of MK 866 on [Ca2+]i levels in cellular systems should 
always be taken into account when evaluating generated data. 
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4 Discussion 
4.1 Sex differential regulation of and hormonal influence 
on p12-LO activity 
Androgens were recently identified to regulate 5-LO activity in isolated 
PMNL and whole blood revealing a possible basis for a sex bias in 
leukotriene (LT) biosynthesis [127]. A different pattern of LT biosynthesis 
results in a varying predisposition for inflammatory diseases in male and 
female [127]. p12-LO activity in human platelets was investigated and a 
similar picture as for 5-LO activity was expected, since p12-LO and 5-LO 
are related enzymes [57]. Freshly isolated washed platelets from male and 
female donors were compared in regard to spontaneous and stimulated p12-
LO activity, AA release, p12-LO subcellular localisation and p12-LO 
expression. Surprisingly, no significant differences could be found in any of 
the points investigated except for AA release in A23187-stimulated cells, in 
contrast to 5-LO where a lower leukotriene biosynthesis was found in male 
cells associated with different 5-LO subcellular localisation caused by 
androgens [127]. 
 
In washed platelets from male and female donors, AA release after A23187-
stimulation differed slightly but significantly between male and female 
platelets. This might explain the tendency for minmal higher 12-HETE 
formation in A23187-stimulated PRP from female donors as compared to 
male PRP. However, this higher p12-LO activity in PRP was not found to be 
statistically significant. Debatable is the comparison of p12-LO activity in 
PRP and AA-release in washed platelets since the experimental conditions 
vary between the two assays. The physiological relevance of observed 
differences in AA release between male and female is unclear. 
 
A lower basal p12-LO product formation in non-stimulated female platelets 
after incubation times of 15 and 120 min was not considered significant. The 
very low amounts of 12-HETE produced during these incubations will not 
have an impact on the overall product formation in stimulated platelets, 
where 12-HETE amounts measured are approx. 10- to 100-fold higher 
depending on stimulus applied. 
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Furthermore, no consistent tendency for higher or lower p12-LO activity in 
stimulated female cells was observed except for this particular incidence in 
A23187-stimulated platelets. Nevertheless, at least in non-stimulated female 
platelets a tendency for lower p12-LO product formation could be detected. 
 
COX-1 activity was monitored in each experiment as control. COX-1 
activity and product amounts did not differ between male and female donors 
neither in washed cells nor in PRP incubations. 
 
Experimentation with washed platelets means to handle cells that have been 
removed from all plasma constituents including sex hormones. To remedy 
this flaw, the influence of sex hormones was reconstituted by addition of sex 
hormones to the washed platelets resuspended in buffer. Progesterone 
impaired p12-LO significantly after 30 min of incubation in non-stimulated 
cells. Estradiol and DHT proved to be ineffective in comparable 
concentrations. This rapid progesterone effect, however, was found to be 
reversible in a very fast manner. As soon as progesterone was removed from 
the incubated sample p12-LO regained almost full activity (90%). This 
observation may explain the lack of significant differences for the p12-LO 
activity between washed platelets from female and male donors since sex 
hormones had been removed during the cell isolation process. 
Astonishingly, no significant difference was found in p12-LO activity in 
PRP incubations from male and female donors where all hormones are still 
present and should affect p12-LO activity. Yet effective concentrations of 
progesterone to impair p12-LO activity were determined to be between 1 
and 3 µM. Such high progesterone concentrations are only reached in 
females during pregnancy, so the missing significant difference between 
male and female PRP is not surprising since progesterone concentrations in 
male and female do not strongly differ during most of the days of the normal 
menstrual cycle and are below 0.1 µM. Still, as mentioned above, a slight 
trend towards lower p12-LO activity in female PRP compared to male PRP 
could be observed.  
Matching the results obtained from male and nonpregnant female PRP 
showing no significant difference in p12-LO product formation, PRP from 
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pregnant donors showed a lower p12-LO activity. However, this lower p12-
LO activity can only in part be attributed to a progesterone influence as also 
COX-1 activity was lower in the samples of pregnant donors. COX-1 
activity however was not influenced by progesterone in any concentration in 
washed platelets. A more complex regulation of p12-LO in pregnant females 
seems likely since complex changes in blood coagulation and composition 
have been detected during pregnancy as well [186] and might also change 
susceptibility of platelets for their agonists and thus the metabolic 
productivity of platelet-residing enzymes. 
Progesterone addition to PRP isolated from male donors did impair p12-LO 
activity, although very slightly. Subsequent progesterone supplementation of 
platelets resuspended in plasma prepared from male donors also slightly 
lowered p12-LO product formation in comparison to controls. Both results 
support a possible influence of progesterone on p12-LO in vivo. However, 
analyzing p12-LO activity in platelets resuspended in plasma isolated from 
pregnant donors at different stages of pregnancy showed no conclusive 
effect. p12-LO activities could not be correlated to different progesterone 
plasma levels. Again, a more complex regulation depending on several 
factors seems obvious. 
 
In general, p12-LO activity was lower in plasma or PRP incubations than in 
platelets incubated in a buffer system. This suggests that plasma may 
contain some p12-LO inhibitory component. Detection of basal p12-LO 
activity in PRP or plasma induced by incubation at 37°C was hardly 
evaluable as product formation was not as clearly discernible as in samples 
from washed platelets. A very strong plasma binding could easily entail this 
low product amount traceable in plasma but would not impair physiological 
function of 12-HETE. Also an apparently low concentration of 12-HETE 
could be compensated by an “omnipresence” of 12-HETE in a constant 
concentration around its target cells or receptors thus continuously 
influencing these possible targets. 
 
p12-LO activity is often linked to the translocation of the enzyme to the 
platelet membrane [95, 98]. Although a translocation of p12-LO from the 
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cytosol was observed upon platelet stimulation, the major amount of p12-LO 
protein present in the cells was already located at the membrane fraction. 
This finding contradicts previous results while supporting others [70, 92]. 
However, an increase of p12-LO amount in the membrane fraction upon 
thrombin or collagen stimulation was not clearly detectable. Translocation 
of p12-LO also was not complete, a very small fraction remained in the 
cytosol even upon thrombin stimulation. Since most of the protein was 
already located at the membranes small increases in the protein 
concentration (by translocation from the cytosol) would probably go 
unnoticed. Interestingly, p12-LO also translocates to the membrane fraction 
without a stimulating impulse just at incubation at 37°C. This spontaneous 
translocation fits to the results of a spontaneous basal 12-HETE formation 
that can be observed in non-stimulated cells. However, a stringent 
connection of stimulus-induced p12-LO translocation and p12-LO activity 
cannot be deduced from these findings alone. 
4.2 Progesterone affects p12-LO activity 
Progesterone belongs to the class of steroid hormones, a category of 
signalling molecules mediating their effects via genomic actions and in the 
classical sense influencing protein expression in a slow mode of action. 
Platelets, however, are anucleate cells. Genomic effects in the classical 
meaning (concerning protein biosynthesis) cannot be monitored in anucleate 
cells as they have no or only limited ability for de novo protein biosynthesis. 
Progesterone is able to potently inhibit p12-LO activity in intact platelets in 
a fast and reversible manner, two characteristics that are not exhibited by 
classic genomic signalling events. Progesterone influences on p12-LO have 
to be attributed to different modes of action of progesterone in platelets for 
the reasons mentioned.  
 
So how does progesterone influence p12-LO activity?  
Progesterone interference with p12-LO activity could basically originate at 
several levels. Progesterone could (1) directly inhibit p12-LO, (2) impair 
substrate supply (AA release), (3) change the subcellular localisation of p12-
LO, (4) alter platelet susceptibility towards external stimuli, (5) influence 
kinase activation states, in particular of PKA.  
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Progesterone does not inhibit p12-LO activity in cell homogenates, a direct 
inhibition of p12-LO can therefore be excluded. Progesterone needs an 
intact cellular environment to mediate its effects. Progesterone influence on 
p12-LO could not be observed after homogenization of platelets incubated 
with progesterone prior to cell disruption. Also, progesterone did not affect 
AA release in intact cells or cPLA2 activity in a cell free system. Thus, a 
lack of substrate supply can also be excluded as effective mechanism for 
reduced p12-LO product formation. Translocation and subcellular 
localisation of p12-LO in platelets and agonist induced aggregation as 
indicators of platelet reactivity were not impaired or changed by 
progesterone pre-treatment of platelets. Measurement of aggregation might 
not be an ideal tool, since progesterone already influences spontaneous p12-
LO activity and aggregation events need to be induced by platelet agonists. 
Alongside progesterone, also estradiol and DHT were tested in varying 
concentrations up to 10 µM. No other hormone showed an impact on p12-
LO activity implying specificity for progesterone. 
 
Progesterone is able to potently influence p12-LO activity in collagen- and 
to a lesser extent in thrombin-stimulated cells. An interference of 
progesterone with intracellular kinase signalling pathways generally induced 
by those two agonists seems likely. One has to keep in mind though, that 
only non-stimulated cells were tested for an influence of progesterone on 
kinase phosphorylation states as the strongest impact of progesterone on 
p12-LO activity was evident in non-stimulated cells. Whether agonist-
induced kinase activation could be changed by progesterone remains a 
subject of further detailed research.  
 
However, none of the kinases normally activated by thrombin or collagen 
stimulation like ERK1/2, p38 or Akt [13, 14, 17] were involved in 
progesterone influence, as progesterone neither enhanced nor impaired 
activation (measured by phosphorylation state) of these kinases in 
comparison to solvent control. Though all kinases directly investigated for 
phosphorylation are involved in platelet activation, progesterone exerts an 
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inhibitory function on p12-LO. Such a negative regulation of p12-LO could 
be mediated by protein kinase A (PKA), a kinase playing a major role in 
platelet inhibition [25]. Interestingly, p12-LO does indeed exhibit a 
phosphorylation motif for PKA assigning p12-LO as a putative PKA target 
[99]. PGE2, a PKA activator was capable to induce a significant p12-LO 
inhibition in platelets. H89, a PKA inhibitor, could partially reverse effects 
of progesterone, supporting a connection of PKA to p12-LO regulation. A 
rapid, non-genomic activation of PKA by progesterone has been described 
in the acrosome reaction of sperm cells [143] and could be the pathway 
leading to p12-LO regulation in platelets as well. 
 
PKA is regulated by intracellular cAMP levels and therefore also known as 
cAMP-dependent PKA [25]. Hence, a cAMP analogue, 8-bromo-cAMP was 
tested for its impact on p12-LO activity. Astonishingly, 8-bromo-cAMP was 
not able to induce a significant inhibition of p12-LO activity. An induction 
of rise in intracellular cAMP levels by progesterone seems unlikely. In own 
studies, even the control PGE2 failed to induce a significant rise in cAMP 
levels (data not shown). However, which level of cAMP is actually needed 
to activate PKA in platelets requests further research. To ascertain p12-LO 
regulation via PKA pathways also phosphorylation status of other PKA 
targets in platelets as GPIbβ [25] and of PKA itself should be analysed after 
progesterone incubation of platelets. Possibly in vitro kinase assays studying 
p12-LO phosphorylation by PKA is a useful tool to reveal the actual 
pathway. Also a regulatory function of PTP (protein tyrosine phosphatases) 
involved in inhibitory platelet regulation [28] could be proposed as possible 
mechanism of PKA activation. 
 
In physiological contexts, p12-LO rather seems to be a constitutively active 
enzyme with possible “house-keeping” functions rather than a dormant 
enzyme that is only activated for special occasions by stimulation [76]. 
Supply of free AA seems sufficient to induce p12-LO product formation. At 
least in platelets p12-LO is unlikely to be an enzyme derived from de novo 
protein synthesis as platelets only have limited potential for protein 
biosynthesis [3]. In this study it was observed that 12-HETE amounts 
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increased as soon as non-stimulated cells were incubated at 37°C, 12-HETE 
concentration accumulating at a plateau concentration after approximately 2 
h. Cells kept on ice for the same period did not produce 12-HETE. More 
importantly, in stimulated cells a sudden increase of p12-LO activity 
overlapped with activation of cPLA2 and subsequent AA release by the 
applied agonists. Strong p12-LO product formation after cell stimulation 
could well be independent from any activating signalling directly pointed at 
p12-LO. This very high p12-LO product formation could simply be due to a 
high substrate supply for p12-LO coinciding with a high capability of p12-
LO to excessively metabolise its substrate. Especially with a background of 
a permanent spontaneous non-stimulated p12-LO activity [75, 76] a negative 
inhibiting regulation of p12-LO seems more probable than a positive 
activating regulation. 
 
Progesterone does not inhibit p12-LO completely but suppresses p12-LO 
activity to a basal level. A certain amount of 12-HETE (approx. 20 ng/108 
cells) is always measured. A permanent attachment of a p12-LO fraction to 
the platelet membranes further supports the hypothesis of a constitutive 
function for p12-LO. Separation of the total p12-LO protein present in 
platelets in two fractions forms a possibility for differential p12-LO 
regulation and even could imply different enzyme purposes in the cell. The 
larger fraction was predominately located at the membranes, the smaller 
fraction in the cytosol dividing p12-LO in a continuously active fraction at 
the membrane and a resting fraction in the cytosol that can be stimulated by 
platelet agonists to high activity. In this way, p12-LO could exert several 
different functions depending on the subcellular distribution and the 
activation state of the cell. 
 
p12-LO activity is influenced by progesterone, but neither by direct 
interactions with p12-LO or cPLA2 nor by overall platelet inhibition. 
Possibly, even though progesterone might not influence AA release directly 
it might hamper the access of p12-LO to free AA or influence p12-LO 
membrane binding at sites where AA is released and thus impede p12-LO 
access to AA. 
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Although involvement of cPLA2 was specifically proposed in AA release 
needed for p12-LO activity [30] different isoforms of PLA2 could be 
responsible for supplying AA as substrate for p12-LO in resting and in 
activated cells. Only cPLA2 activity was considered in the present study. 
However, other PLA2 isoforms supplying p12-LO in basal conditions could 
be influenced by progesterone impairing p12-LO activity. 
4.3 Physiological implications of progesterone regulation 
of p12-LO activity 
During pregnancy progesterone plasma concentrations reach levels that 
could influence p12-LO activity in vivo. Especially towards the end of 
pregnancy in the 3rd trimester, plasma progesterone concentrations rise to 1 
µM and even above. These levels are not reached during the normal 
menstrual cycle. Pregnancy itself is characterized by immense changes of 
endometrial and uterine tissues. To sustain pregnancy, new tissue and new 
vessels have to be built up to secure a rich supply of nutrients for the 
embryo. At the end of pregnancy, angiogenesis and endometrial tissue 
growth slow down as the body prepares for giving birth. Although the 
situation during pregnancy cannot be compared with the excessive growth 
and angiogenesis observed for cancer and tumour growth, certain 
similarities concerning formation of new blood vessels and the high growth 
rate of cells can be discovered. 
 
p12-LO has been brought into connection with angiogenesis and a 
supportive function for high metastatic potential and high growth rate of 
certain cancers. These properties could be important for angiogenesis during 
pregnancy to a certain extent supporting the immense changes in the uterus. 
In fact, a p12-LO is expressed in uterine cervical tissues [187, 188] and 
could contribute with its activity to angiogenesis and endometrial growth 
during the first two trimesters of pregnancy. During this time progesterone 
plasma levels are < 1 µM and therefore too low to significantly affect p12-
LO activity. As soon as pregnancy nears full term, progesterone 
concentrations rise to levels inhibiting p12-LO activity. The diminished 
output of 12-HETE may then slow angiogenesis and endometrial growth. 
 
  106 
Even though plasma levels of 1 µM progesterone are not reached during 
menstruation, a possible regulation of p12-LO by lower progesterone levels 
is possible. Induction of endometrial tissue shedding and influence on blood 
coagulation by progesterone during menstruation could be completed by 
progesterone regulation of p12-LO activity. Rise in progesterone levels in 
the follicular phase could lead to a slight suppression of p12-LO activity and 
onset of endometrial shedding as proliferative effects of 12-HETE are 
suppressed. During menstruation blood clotting is lower than that of normal 
blood [189]. Beside other factors, even a slight suppression of p12-LO could 
possibly contribute to a higher threshold for platelet activation and thus to a 
lower blood coagulation as p12-LO activity is important for platelet 
activation [103]. 
 
A potential for physiological functions of p12-LO activity lies in the 
effectiveness of its metabolite 12-HETE as chemotactic agent for leukocytes 
[116]. Suppression of p12-LO activity by progesterone would lead to lower 
12-HETE concentration and therefore to a decreased infiltration of 
leukocytes into endometrial tissues during the secretory phase of the cycle. 
After progesterone withdrawal, infiltration of uterine tissues by leukocytes 
would increase with a resumed activity of p12-LO and higher local 12-
HETE concentrations. A stronger presence of leukocytes could probably 
increase the local concentration of PG that lead to uterus contraction and 
support endometrial shedding.  
 
How, and if 12-HETE plays a role as chemotactic factor in pregnancy and 
preparation of birth cannot conclusively be assessed, although a differential 
effect of progesterone depending on its concentration in the target tissue 
should be investigated. This proposed biased function of progesterone 
promoting different actions in different concentrations most probably is 
accurate for p12-LO regulation by progesterone. On the other hand, 
opposing functions can be proposed for p12-LO and 12-HETE involvement 
in pregnancy and the normal menstrual cycle.  
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Nevertheless, p12-LO functions may contribute only in a moderate manner 
in pregnancy and menstruation since the majority of progesterone properties 
affect protein expression and genomic regulations of uterine tissues. 
 
Women do have higher mean plasma levels of progesterone during 
menstruation. Accordingly, a trend for lower p12-LO product formation in 
platelets could be observed in the present study.  
 
It is a well known fact that more men (lower mean progesterone levels) are 
suffering from cardiovascular disease than women. Cardiovascular events 
are often preceded by a history of high blood pressure and are a result of a 
higher responsiveness of platelets. p12-LO was connected to platelet 
aggregation as well as it has recently been found to influence blood pressure 
[103, 152]. In patients with essential hypertension, an elevated urinary 
excretion of 12-HETE has been surveyed attributing a possible role for p12-
LO activity and its metabolites in hypertension [190]. If progesterone would 
lower the basal p12-LO activity in females thereby inducing a 
fundamentally lower blood pressure and a lower susceptibility of platelets 
for their activating agonists, higher progesterone plasma levels could partly 
explain the lower incidence of cardiovascular disease in women as 
compared to men. 
 
More studies on other 12-lipoxgenases possibly influencing blood pressure 
and platelet aggregation to progesterone have to be conducted. 
4.4 Rapid non-genomic effects of sex hormones in 
platelets 
Traditionally, effects of sex hormones are expected to be mediated by 
genomic regulation of their target cells. For this purpose, a functional 
nucleus containing genomic DNA and a transcriptional machinery is a 
prerequisite. Progesterone binds to its receptor, the hormone-receptor 
complex translocates to the nucleus and induces transcription of DNA after 
binding to hormone response elements in the nucleus [140]. Recently, also 
fast, non-genomic effects have been described for sex hormones directly 
activating kinase cascades or other fast regulatory mechanisms along with 
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progesterone receptors located in the cell membranes [138, 139]. However, 
those rapid effects probably mediated by membrane progesterone receptors 
have so far only been described for nucleated cells or for hormone 
concentrations far higher (10 µM or more) than the physiological range 
[180]. Moreover, effects described so far could not be linked to definite 
intracellular events, i.e., regulation of enzyme functions. In this study an 
effect of progesterone in a physiological range could be observed in 
anucleated cells (human platelets) for the first time causing an inhibition of 
p12-LO activity. This observation opens a completely novel field of research 
(also see 4.5), especially as platelets are key players in aggregation and also 
cardiovascular diseases. A regulation of platelet functions by sex hormones 
is of great interest as a clear bias exists in the incidence of cardiovascular 
events (also see 4.5). 
4.5 Progesterone receptors on platelets 
Mediation of progesterone effects is thought to primarily occur via 
progesterone receptors. Several receptors have been identified so far 
including the classical receptors PR-A and PR-B transmitting progesterone 
effects in a genomic manner. Also membrane-located progesterone receptors 
(mPR) have been identified. They are characterized by smaller size and 
mediate rapid non-genomic effects. Progesterone actions, probably mediated 
by binding to these mPR, could not be blocked by the progesterone receptor 
antagonist mifepristone [140]. In the present study no classical progesterone 
receptors could unambiguously be identified to be present in platelets 
whereas estradiol and androgen receptors were identified in platelets before 
[191]. The progesterone effect monitored in platelets could also not be 
blocked by mifepristone. A yet undiscovered mPR in platelets responsible 
for mediating regulation of p12-LO activity by progesterone seems the only 
possibility for the manifestation of rapid progesterone effects and has yet to 
be fully revealed. 
4.6 p12-LO inhibitor and its pharmacological profile in 
platelets 
CDC was first described as a selective 12-LO inhibitor [147]. Nowadays, it 
is commonly used as a pharmacological tool to investigate the contribution 
or involvement of 12-LO and its metabolite 12-HETE in different cell types 
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and also in animal studies. Here we show that CDC inhibits p12-LO but also 
COX-1 activity in intact platelets. Accordingly, approaches applying CDC 
as selective 12-LO inhibitor to elucidate involvement of 12-LO pathways in 
cancer development or hypertension [153, 192] could easily lead to false 
results since CDC may act also by suppressing COX activity. To reveal the 
pharmacological profile of CDC, its effects on intact cells, cell homogenates 
and cell free enzymes were investigated more closely. 
 
In intact platelets, IC50 of 0.3 to 11 µM for p12-LO and COX-1 were 
determined with lowest IC50 for collagen-stimulated cells (Table 4). In 
A23187-stimulated cells COX-1 was more potently inhibited than p12-LO 
indicating different points of attack for COX-1 activity and for p12-LO in 
the cell. 
 
Enzyme 
                 Stimulus 
Thrombin Collagen A23187 AA 
p12-LO 1 µM 0.3 µM 11 µM > 30 µM 
COX-1 1 µM 2 µM 3 µM 10 µM 
Table 4 IC50 of CDC determined for p12-LO and OCX-1 in intact platelets 
 
Surprisingly, supplementation of AA led to a complete loss of CDC 
inhibitory potential for p12-LO. This may indicate that CDC blocks 
endogenous AA supply. On the other hand, COX-1 activity was still 
potently impaired in the presence of exogenously added AA. Since CDC 
was also able to inhibit ROS formation in intact platelets in thrombin- and 
collagen-stimulated platelets, an additional influence on platelet functions in 
certain scenarios seems plausible.  
 
CDC may act via suppression of cPLA2 to impair AA supply. p12-LO 
activity is most likely regulated by substrate supply, which is provided by 
exogenous addition of AA or by strong stimulus (e.g., A23187) explaining 
the loss of CDC inhibitory potential in AA-supplemented cells and the 
higher IC50 for A23187-stimulated cells. COX-1 activity however is also 
closely regulated by intracellular redox state and [Ca2+]i levels and might 
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thus be stronger influenced by CDC than p12-LO. p12-LO might also 
receive AA from a different PLA2 isoform than COX-1 (see 4.2) and be less 
affected by cPLA2 inhibition. 
 
In thrombin- and collagen-stimulated cells a major inhibitory mechanism for 
CDC is probably mediated by deprivation of substrate AA for p12-LO and 
COX-1. CDC potently blocks [Ca2+]i mobilisation in thrombin- and 
collagen-stimulated cells. Although cPLA2, responsible for AA release in 
stimulated platelets, is not directly inhibited unless at very high 
concentrations (30 µM), inhibition of [Ca2+]i mobilisation by CDC keeps 
[Ca2+]i levels low and prevents effective cPLA2 activation. Both p12-LO and 
COX-1 are influenced by CDC in this way mainly via substrate withdrawal. 
 
In case of AA supplementation, p12-LO activity is only scarcely impaired 
whereas COX-1 activity is strongly inhibited. CDC was able to potently 
prevent ROS formation in platelets changing the intracellular redox state of 
the cells. This second influence alters COX-1 metabolic activity despite 
ample exogenous substrate supply but not p12-LO activity. An impact on 
intracellular ROS formation was previously described for CDC although a 
connection was only made to 12-LO inhibition and not to a direct inhibitory 
effect of CDC on ROS formation itself [193]. Again, a different regulatory 
pattern for both enzymes emerges. p12-LO seems to be less or even not 
dependent on intracellular redox tone as compared to COX-1. 
 
A direct inhibition of COX-1, COX-2 and cPLA2 by CDC was not found in 
cell-free assays. On the other hand, COX-1 was still potently inhibited in 
platelet homogenates suggesting an important function for lipid matrices 
(membrane fractions present in platelet homogenates) for CDC inhibition on 
the respective enzymes. Inhibition of p12-LO in homogenates implies direct 
influence of p12-LO activity by CDC possibly via redox activity. 
Nonetheless, also for p12-LO inhibition multiple factors may contribute to 
the inhibitory effect seems likely. 
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Inhibitory properties of CDC culminate in its ability to influence general 
platelet activation displayed by its impairment of collagen-stimulated 
platelet aggregation. A concentration of 30 µM CDC inhibited platelet 
aggregation even more potently than the control inhibitor indomethacin. 
Thrombin-, U46619- and AA-stimulated aggregation however, was not 
impaired even when applying high concentrations (30 µM) of CDC. In 
thrombin-stimulated platelets CDC inhibits COX-1 activity and therefore an 
effect of CDC on aggregation in thrombin-stimulated cells should be 
observed. Apparently, CDC interacts with kinase signalling induced by 
collagen but not with signalling events induced by the other platelet 
agonists. ROS formation, [Ca2+]i mobilisation and p12-LO activation in 
collagen-stimulated platelets are most potently affected supporting a 
proposed interference with kinase signalling pathways induced by collagen 
in platelets. CDC also inhibits TXB2 formation in intact washed platelets 
and whole blood reflecting the lower COX-1 activity. 
 
Further studies employing CDC as a pharmacological tool to distinguish the 
involvement of 12-LO and/or COX enzymes in intracellular signalling 
events have to take into account additional cellular effects of CDC (e.g., 
[Ca2+]i signalling, redox state, etc.). Reasonable development of CDC as a 
possible anti-platelet drug should also be considered as CDC interferes with 
certain properties typical for platelet inhibitors.  
4.7 FLAP inhibitor MK-886 and its effect in intact platelets 
MK-886 is a very potent FLAP inhibitor (2.5 nM) impairing 5-LO activity 
and leukotriene biosynthesis [157]. It is often used as a pharmacological tool 
to investigate the role of the 5-LO pathway in many inflammatory diseases 
and also applied in studies related to cancer, as MK-886 is able to induce 
apoptosis of cancer cells in concentrations up to 50 µM [163].  
 
In platelets however, MK-886 has a completely different effect that has not 
been described for this cell type, yet. MK-886 strongly increased the 
formation of AA metabolites in platelets. It also potently induced [Ca2+]i 
mobilisation in a concentration range of 10 to 50 µM. A similar effect on 
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[Ca2+]i mobilisation has been already described for PC-3 and other cells 
[168, 169].  
The [Ca2+]i mobilisation in platelets possibly accounts for the strong 
increase in free AA triggering a high product formation of COX-1 and 
especially p12-LO. The strongest effect is produced at a concentration of 10 
µM MK-886. The effect of MK-886 is not observed in cells exogenously 
supplemented with 10 µM AA or in cell homogenates. Therefore, an impact 
of MK-886 on AA release and the need for an intact cellular environment is 
obvious. Moreover, 10 µM MK-886 induced [Ca2+]i mobilisation in 
platelets. Hence, an activation of cPLA2 by increased [Ca2+]i levels seemed 
the most evident explanation for this phenomenon. On the other hand, the 
achieved increase in [Ca2+]i at 10 µM MK-886 seemed too weak to explain 
this strong increase in p12-LO and COX-1 product formation simply by 
cPLA2 activation. At 30 µM MK-886, [Ca2+]i influx induced is comparable 
with [Ca2+]i mobilisation induced by platelet agonists like thrombin. 
Therefore, whether MK-886 causes p12-LO activity by elevation of [Ca2+]i 
is questionable. 
 
FLAP is able to bind and transfer AA to 5-LO [156], and MK-886 as a 
FLAP inhibitor interferes with this function. Therefore, a proposed 
interference of MK-886 with reincorporation of AA into the platelet 
membranes offers a more suitable explanation for the MK-886 effect in 
intact platelets. An accumulation of AA instead of an active increased 
release would explain the enhanced p12-LO activity. 30 µM MK-886, 
although inducing a stronger [Ca2+]i mobilisation, does not increase p12-LO 
and COX-1 activities but rather reduces product amounts in comparison to 
values at 10 µM MK-886. MK-886 potently inhibits COX-1 activity [157] 
and possibly also p12-LO activity or induces additional effects at those high 
concentrations.  
 
MK-886 also affects [Ca2+]i levels in PMNL expressing 5-LO, an enzyme of 
the AA cascade strongly dependent on [Ca2+]i as cofactor. However, 
effective concentrations for [Ca2+]i elevation are found at a concentration of 
about 50 µM MK-886, concentrations that are not applied in studies 
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concentrating on 5-LO activity and leukotriene signalling. Licofelone, 
another FLAP inhibitor [185], caused [Ca2+]i mobilisation in PMNL at 
concentrations between 30 and 50 µM (data not shown). Structural 
similarities between MK-886 and licofelone probably are the connecting 
element for effects observed for both substances. 
 
[Ca2+]i signalling and [Ca2+]i levels are very strongly affecting intracellular 
processes in almost every cell type, whether kinase phosphorylation or 
metabolic regulation is concerned. A pharmacological tool strongly 
influencing [Ca2+]i signalling when applied in common concentrations 
should not be used without consideration of possible side effects. 
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5 Conclusion 
Platelet-type 12-lipoxgenase was the first lipoxygenase to be identified in 
mammalian tissues [44]. In spite of ongoing research to expand the 
knowledge on regulation of p12-LO activity, no signalling pathways 
controlling p12-LO activity have been identified so far. p12-LO is involved 
in the development of certain cancers [105] and takes part in hypertension 
and platelet aggregation [103, 190]. A detailed pharmacological profile 
enclosing regulatory factors and possible inhibitors could pose new starting-
points for medical treatments of disorders where p12-LO plays a potential 
role. In particular, cardiovascular diseases seem to be influenced by p12-LO 
activity. Research of sex influences on p12-LO activity was enclosed in this 
study since a clear sex bias in the incidence of cardiovascular events has 
been a long known fact [128]. 
 
Basic research regarding possible gender differences in the regulation of 
p12-LO was issued in this study. p12-LO activity is not significantly 
different between isolated male and female platelets. Progesterone, however, 
impairs p12-LO activity by a pathway possibly involving PKA as effector 
kinase. A trend for a lower p12-LO basal activity in females could be 
observed. This very small difference could support a lower susceptibility of 
women for cardiovascular disease before menopause mediated by a slightly 
higher progesterone level in women as compared to men. A possible role for 
progesterone regulation of p12-LO in pregnancy and menstruation could be 
connected to angiogenesis, endometrial growth and shedding, although 
further investigations will have to be performed. 
A mechanism of hormonal regulation in platelets by rapid, non-genomic 
actions of progesterone led to a proposition of a new progesterone receptor 
located in platelet membranes. 
 
p12-LO could be defined as a permanently active enzyme dependent on 
inhibitory regulation rather than on activating agonists for a regulation of its 
activity. Possible physiological functions for a constitutive p12-LO activity 
in vivo seem likely as p12-LO activity is not completely suppressed by 
progesterone as a proposed in vivo regulator. 
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CDC and MK-886, commonly and widely used as tools to connect 12-LO or 
the 5-LO pathway to respective functionality, were identified to be 
suboptimal pharmacological tools if applied without further thought. Both 
inhibitors show broad and unspecific pharmacological effects including 
influence on [Ca2+]i mobilisation and ROS formation. Both these events 
influenced by CDC and MK-886 outside their inhibitory range have a strong 
impact on several other intracelular functions. For example, changes in 
[Ca2+]i levels are often a precursor reaction to major signalling events in the 
cell. Impact of pharmacological tools on [Ca2+]i and ROS formation imply 
an influence of these tools on many more functions than their indented 
targets and complicate an interpretation of observed events. 
 
In conclusion, p12-LO poses an interesting subject for investigation of 
mechanisms underlying sex related incidences in certain diseases. Especially 
in anucleate platelets hormone regulation of intracellular events seemed 
unlikely. Interestingly, those cells and their enzymes are targets for rapid 
non-genomic effects giving interesting new insights in intracellular 
regulation events in platelets. Finally, p12-LO should be considered as an 
interesting target for new agents impeding p12-LO activity in cancer 
treatment and in therapy of hypertension and cardiovascular diseases taking 
into account the sex hormonal status of the respective subject. 
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6 Summary 
The first mammalian lipoxygenase to be discovered in 1974 was platelet-
type 12-lipoxygenase (p12-LO) which was named for the site of its 
discovery. It belongs to a large family of non-heme dioxygenases including 
5-lipoxygenase responsible for leukotriene biosynthesis. Although p12-LO 
was the first lipoxygenase in mammals to be discovered and research has 
been going on since the discovery, only very little is known about regulation 
of activity. Involvement in cancer, angiogenesis, hypertension and platelet 
activation could be attributed to p12-LO activity and its metabolite 12-
HETE and suggests the necessity of intensified research. For this study a 
focus was put on probable regulation in a sex dependent manner, as 
androgens had recently been found to be involved in regulation of 5-LO and 
leukotriene biosynthesis. Additionally, in particular for cardiovascular 
diseases a gender bias with higher incidence in male has been a long 
established fact, so a possible sex dependent regulation of p12-LO was 
proposed. 
To explore p12-LO regulation in general and to elucidate possible sex 
dependent regulation in particular, a characterisation of p12-LO regulation 
in platelets was attempted in this work with two different approaches.  
One, gender differences in regulation of p12-LO and possible influences of 
sex hormones were investigated. Two, common pharmacological tools, CDC 
and MK-886, were used to elucidate possible properties of p12-LO in intact 
cells. 
 
Platelet 12-lipoxygenase is not differently active between the two sexes 
whether in non-stimulated and stimulated platelets. No differences were 
manifest in release of AA, subcellular localisation, translocation pattern or 
protein amount of p12-LO compared in platelets from male and female 
donors. However, a slight tendency towards lower product formation in 
female platelets was observed.  
A strong spontaneous p12-LO activity was measured in non-stimulated 
platelets and metabolic activity continued over log time periods. p12-LO 
activity could strongly be enhanced by platelet stimulation with thrombin, 
collagen, A23187 and arachidonic acid. However, a direct induction of p12-
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LO activity by these agonists seems improbable. Platelet stimulation rather 
strongly increases the amount of available substrate for p12-LO as cPLA2 is 
activated and AA released than activates p12-LO itself. 
 
p12-LO activity was potently and selectively suppressed to a basal level by 
addition of 1 to 3 µM progesterone in a fast and non-genomic manner. 
Application of the other sex hormones estradiol and DHT failed to show an 
effect on p12-LO activity. Only p12-LO was affected by progesterone, other 
enzymes metabolizing AA as cPLA2 and COX-1 were not affected in any 
circumstances. [Ca2+]i levels, platelet aggregation, subcellular localisation 
and translocation pattern of p12-LO were not influenced by progesterone. A 
direct inhibition of p12-LO by progesterone could furthermore be excluded 
as no progesterone effect could be observed in homogenate incubations. 
p12-LO activity is not complete blocked by progesterone but only 
suppressed to a basal level supporting evidence for p12-LO role as a “house-
keeping” enzyme in physiological contexts. 
 
Surprisingly, the hormone progesterone normally acting on genomic levels 
affects its target enzyme p12-LO in anucleate cells, in platelets. 
Progesterone impairs p12-LO activity in a rapid, reversible manner as 
opposed to classical genomic actions. This progesterone effect is possibly 
mediated by a novel progesterone receptor (mPR) localized in the platelet 
membranes. Regulation pathways could be identified to involve activation 
of PKA and ascertain a negative, deactivating regulation of p12-LO activity 
in stimulated and in non-stimulated cells. PKA most likely converts its 
influence on p12-LO possibly by phosphorylation of the enzyme as p12-LO 
contains a phosphorylation motif for PKA. 
 
In vivo progesterone levels reached during pregnancy overlap with effective 
progesterone concentrations for an inhibition of p12-LO in vitro (0.3 to 1 
µM). Attempts to transfer in vitro findings to in vivo conditions showed that 
progesterone could slightly suppress p12-LO activity in male PRP. 
Moreover, p12-LO activity in PRP prepared from pregnant females was 
lower than in controls from male and female. Both findings support an in 
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vivo relevance for the progesterone regulation of p12-LO activity although 
progesterone probably contributes only marginally to regulation of p12-LO, 
so more complex mechanisms adding to this effect should be expected. 
 
CDC revealed many more complex properties than just a 12-LO inhibitor 
was suspected to display. CDC not only inhibited p12-LO activity, but 
affected platelet functions on levels of ROS formation, [Ca2+]i mobilisation 
and aggregation and also potently inhibited COX-1 activity in platelets. MK-
886 as FLAP inhibitor should not affect p12-LO activity in intact platelets at 
all, as platelets do not express FLAP or a likewise enzyme. However, 10 µM 
MK-886 potently increases p12-LO activity approximately 40-fold probably 
due to an inhibition of AA reincorporation into the cellular membrane 
increasing substrate amounts available for p12-LO metabolism. An increase 
of available AA leads to an increase of p12-LO activity sustaining p12-LO 
properties as enzyme mostly independent from stimulatory agents but 
dependent on negative, inhibitory regulation. 
 
To conclude: p12-LO activity is not significantly different in male and 
female platelets, although a slight tendency to lower activity in female was 
proposed. Regulation of p12-LO activity by progesterone gave a surprising 
yet promising novel effect of sex hormones conveyed in anucelate cells. 
This contributes to (1) a better insight in p12-LO activation and regulation 
and (2) understanding rapid non-genomic actions of sex hormones on 
intracellular events. Fundamental properties of p12-LO could be clearly 
defined identifying p12-LO as permanently active enzyme with putative 
“house-keeping” functions in vivo. 
For treatment of various diseases connected to p12-LO activity a better 
understanding of p12-LO is vital and understanding of its basic functions 
and regulation needs to be enforced. 
CDC and MK-886 are useful pharmacological tools with a far wider range 
of possibilities and effects than it was known before. They should only be 
applied considering those new findings carefully for their probable impact 
on events investigated.
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7 Zusammenfassung 
Die erste in Säugetieren gefundene 12-Lipoxygenase wurde 1974 entdeckt 
und nach ihrem Entdeckungsort als Thrombozyten- oder platelet-type 12-
Lipoxygenase (p12-LO) bezeichnet. Sie gehört zu einer großen Familie von 
non-heme Dioxygenasen, die unter anderem die 5-LO einschließt. Diese ist 
an der Leukotrienbiosynthese maßgeblich beteiligt. Obwohl die p12-LO die 
erste entdeckte Säugetier-Lipoxygenase war und die Forschung seit der 
Entdeckung nicht nachgelassen hat, ist bisher nur wenig über die Regulation 
ihrer Aktivität bekannt. Die Rolle der p12-LO und ihres Hauptproduktes 12-
HETE in der Krebsentstehung, bei der Angiogeneseregulation und der 
Entstehung von Bluthochdruck sowie in der Regulation der 
Thrombozytenaktivierung macht die Notwendigkeit für intensive Forschung 
deutlich. Für die vorliegende Arbeit wurde ein besonderer Augenmerk auf 
die mögliche geschlechtsabhängige Regulation der p12-LO gerichtet, da 
kürzlich für das verwandte Enzym 5-LO eine Aktivitätsregulation und damit 
eine Regulation der Leukotrienbiosynthese durch Androgene beschrieben 
wurde. Gerade für kardiovaskuläre Erkrankungen, bei denen der Einfluss der 
p12-LO postuliert wird, ist ein geschlechtsabhängiges Ungleichgewicht in 
der Inzidenz bekannt. Deshalb wurde auch die p12-LO auf eine mögliche 
geschlechtsabhängige Regulation untersucht. 
 
Um die Regulation der p12-LO im Allgemeinen und mögliche Einflüsse des 
Geschlechts auf die p12-LO im Speziellen zu untersuchen, wurden zwei 
Herangehensweisen ausgewählt. Zum einen wurden geschlechtsspezifische 
Unterschiede der p12-LO Aktivitätsregulierung und mögliche direkte 
Einflüsse von Geschlechtshormonen auf die p12-LO untersucht. Zum 
anderen kamen zwei typische pharmakologische Werkzeuge – CDC und 
MK-886 – zum Einsatz, um mögliche Regulationsmechanismen und 
Eigenschaften der p12-LO in intakten Thrombozyten zu beleuchten. 
 
Die p12-LO zeigte keine Aktivitätsunterschiede zwischen Thrombozyten 
von männlichen und weiblichen Spendern, ob in unstimulierten oder 
stimulierten Zellen. Weiterhin konnten beim Vergleich von männlichen und 
weiblichen Zellen weder Unterschiede im Bezug auf AA-Freisetzung noch 
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bei subzellulärer Lokalisation, Translokationsmustern oder Proteinmenge 
der p12-LO festgestellt werden. Allerdings ließ sich eine leichte Tendenz zu 
geringerer Produktbildung in weiblichen Zellen feststellen. 
In unstimulierten Thrombozyten wurde eine ausgeprägte spontane Aktivität 
der p12-LO gemessen, die kontinuierlich über längere Zeiträume anhielt. 
Diese basale Aktivität wurde durch Stimulation der Zellen mit Thrombin, 
Collagen, A23187 Ionophor oder AA deutlich verstärkt. Allerdings scheint 
eine direkte Aktivierung der p12-LO unwahrscheinlich, vielmehr erhöht die 
Thrombozytenaktivierung das Angebot an freier AA und damit die Aktivität 
der p12-LO deutlich, da durch die Stimulation die cPLA2 zur AA-
Freisetzung angeregt wird. 
 
Die Aktivität der p12-LO wird durch Zugabe von 1 bis 3 µM Progesteron 
wirksam und selektiv auf einem basalen niedrigen Niveau gehalten. Der 
beobachtete Effekt tritt – anders als genregulatorische Effekte – schnell ein 
und ist reversibel. Behandlung der Zellen mit anderen Geschlechtshormonen 
wie Estradiol und DHT ergab keinen Effekt auf die p12-LO. Außerdem wird 
nur die p12-LO von Progesteron in seiner Aktivität beeinflusst, andere 
Enzyme des AA-Stoffwechsels wie cPLA2 und COX-1 werden in ihrer 
Aktivität nicht eingeschränkt. Auch intrazelluläre Calciumkonzentration, 
Thrombozytenaggregation, subzellulare Lokalisation und Translokation der 
p12-LO wurden von Progesteron nicht verändert. Eine direkte Interaktion 
der p12-LO mit Progesteron konnte ausgeschlossen werden, da durch 
Progesteronzusatz zu Thrombozytenhomogenaten keine Inhibition der p12-
LO beobachtet wurde. 
Die p12-LO Aktivität wird durch Progesteron nicht vollkommen 
unterdrückt, sondern nur auf ein basales Niveau reduziert. Diese Tatsache 
unterstützt die Vermutung, dass p12-LO wahrscheinlich als „house-keeping 
enzyme“ im physiologischen System eine Rolle spielt. 
 
Überraschenderweise kann das Hormon Progesteron, das gemeinhin seine 
Funktion auf genomischer Ebene erfüllt, sein Zielenzym auch in kernlosen 
Zellen, den Thrombozyten, beeinflussen – und zwar in schneller, reversibler 
Weise, ganz anders als für klassische genomische Effekte zu erwarten wäre. 
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Diese Wirkung des Progesterons wird vermutlich über einen neuartigen 
Progesteronrezeptor (mPR) vermittelt, der in den Membranen der 
Thrombozyten lokalisiert sein könnte. Als Endpunkt der angestoßenen 
Signalwege konnte die PKA als mögliche Effektorkinase identifiziert 
werden, die eine negative, deaktivierende Regulation der p12-LO in 
stimulierten und unstimulierten Thrombozyten sicherstellt. 
Höchstwahrscheinlich übt PKA ihren Effekt auf p12-LO durch 
Phosphorylierung aus, die Sequenz der p12-LO enthält ein entsprechendes 
Erkennungsmotiv für die PKA. 
 
Progesteron-Plasmaspiegel in vivo erreichen während der Schwangerschaft 
Werte, die sich in vitro als effektive Konzentrationen zur p12-LO-Inhibition 
erwiesen hatten. Um mögliche in vivo Wirkungen des Progesterons 
abschätzen zu können, wurde Progesteron zu PRP von männlichen Spendern 
zugesetzt und die Aktivität der p12-LO vermessen. Eine leichte Hemmung 
der Aktivität wurde beobachtet. In PRP von schwangeren Spenderinnen 
konnte ebenfalls eine geringere Aktivität der p12-LO festgestellt werden. 
Beide Ergebnisse zeigen, dass auch in vivo eine Regulation der p12-Lo 
durch Progesteron in Betracht gezogen werden sollte. Allerdings ist zu 
erwarten, dass Progesteron nur einen kleinen Beitrag im 
Regulationsgeschehen leistet und darüber hinaus komplexere Mechanismen 
an der Regulation der p12-LO beteiligt sind. 
 
CDC offenbarte sich als deutlich vielseitiger als von einem p12-LO-
Inhibitor zu erwarten gewesen wäre. CDC hemmte nicht nur die p12-LO-
Aktivität, sondern beeinflusste die Thrombozytenfunktion im Bezug auf 
ROS-Produktion, Calciummobilisierung und Aggregation. Außerdem wurde 
auch COX-1 in Thrombozyten potent in seiner Aktivität gehemmt. Für MK-
886 als FLAP-Inhibitor wurde keinerlei Effekt auf die p12-LO Aktivität 
erwartet, da Thrombozyten höchstwahrscheinlich kein FLAP oder ein 
verwandtes Protein exprimieren. Nichtsdestotrotz steigerte MK-886 in einer 
Konzentration von 10 µM die p12-LO Aktivität etwa 40-fach. Aller 
Wahrscheinlichkeit nach inhibiert MK-886 die Reinkorporation freigesetzter 
AA in die Zellmembran und führt so zu einer Akkumulation an AA in den 
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Zellen. Allein dieses erhöhte Angebot an Substrat (AA) erhöht die p12-LO 
Aktivität, was die Unabhängigkeit der p12-LO von stimulierenden 
Agonisten stärker herausstellt und eine eher negative Regulation der 
Aktivität wahrscheinlich macht. 
 
Zusammenfassend lässt sich sagen, dass keine signifikanten Unterschiede in 
der p12-LO-Aktivität zwischen männlichen und weiblichen Thrombozyten 
bestehen, obwohl eine Tendenz zu geringere Aktivität in weiblichen Zellen 
beobachtet wurde. Die Regulation intrazellulärer Vorgänge durch 
Geschlechtshormone in kernlosen Zellen war ein überraschender und 
zugleich viel versprechender neuer Effekt, der dazu beiträgt, (1) einen 
besseren Einblick in die Regulation der p12-LO zu erhalten und (2) schnelle 
nicht-genomische Effekte von Geschlechtshormonen und ihren Eingriff in 
intrazelluläre Vorgänge besser zu verstehen. Grundsätzliche Eigenschaften 
der p12-LO konnten klar definiert werden, wie zum Beispiel die mögliche 
Funktion als „house-keeping enzyme“ in vivo aufgrund der kontinuierlichen 
Aktivität.  
Um Therapiemöglichkeiten für bestimmte Krankheiten, an deren Entstehung 
die p12-LO beteiligt ist, optimieren zu können, ist ein besseres Verständnis 
der p12-LO unerlässlich und die Erforschung ihrer Grundfunktionen und 
Aktivitätsregulation sollte vorangetrieben werden. 
CDC und MK-886 sind nützliche pharmakologische Werkzeuge mit weit 
größeren Möglichkeiten und Wirkungen als bisher gedacht. Sie sollten nur 
nach sorgfältiger Abwägung eventueller weitergehender Wirkung auf den zu 
untersuchenden Effekt eingesetzt werden. 
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